EP1863812A4 - Dipeptidylpeptidase-iv-inhibierende verbindungen, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese als wirkstoffe enthalten - Google Patents
Dipeptidylpeptidase-iv-inhibierende verbindungen, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese als wirkstoffe enthaltenInfo
- Publication number
- EP1863812A4 EP1863812A4 EP06732744A EP06732744A EP1863812A4 EP 1863812 A4 EP1863812 A4 EP 1863812A4 EP 06732744 A EP06732744 A EP 06732744A EP 06732744 A EP06732744 A EP 06732744A EP 1863812 A4 EP1863812 A4 EP 1863812A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- trifluoromethyl
- amino
- oxo
- butyl
- dihydropyrido
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 485
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 title claims abstract description 34
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- 238000000034 method Methods 0.000 title abstract description 28
- 239000013543 active substance Substances 0.000 title abstract description 8
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 title description 32
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims abstract 4
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims abstract 2
- -1 3-thiophene Chemical compound 0.000 claims description 160
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 66
- 150000003839 salts Chemical class 0.000 claims description 59
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 39
- 229910052739 hydrogen Inorganic materials 0.000 claims description 37
- 239000001257 hydrogen Substances 0.000 claims description 35
- 125000000217 alkyl group Chemical group 0.000 claims description 29
- 229910052736 halogen Inorganic materials 0.000 claims description 25
- 150000002367 halogens Chemical group 0.000 claims description 25
- 150000002431 hydrogen Chemical group 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 17
- 206010012601 diabetes mellitus Diseases 0.000 claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 239000001301 oxygen Substances 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 229910052757 nitrogen Chemical group 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 239000011593 sulfur Chemical group 0.000 claims description 4
- GJAGXFGOQJDHMG-HIFRSBDPSA-N (5r)-1-[(2s)-2-amino-4-[2-(3,4-difluorophenyl)-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5-methylpiperidin-2-one Chemical compound C1[C@H](C)CCC(=O)N1C[C@@H](N)CC(=O)N1CC(N=C(N=C2C(F)(F)F)C=3C=C(F)C(F)=CC=3)=C2CC1 GJAGXFGOQJDHMG-HIFRSBDPSA-N 0.000 claims description 3
- DJNMQSVECLAYMK-ZBFHGGJFSA-N (5r)-1-[(2s)-2-amino-4-[2-cyclopentyl-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5-methylpiperidin-2-one Chemical compound C1[C@H](C)CCC(=O)N1C[C@@H](N)CC(=O)N1CC(N=C(N=C2C(F)(F)F)C3CCCC3)=C2CC1 DJNMQSVECLAYMK-ZBFHGGJFSA-N 0.000 claims description 3
- QXBFXIKTQCKASH-AAEUAGOBSA-N (6s)-4-[(2s)-2-amino-4-[2-cyclopropyl-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-6-methylmorpholin-3-one Chemical compound O=C1CO[C@@H](C)CN1C[C@@H](N)CC(=O)N1CC(N=C(N=C2C(F)(F)F)C3CC3)=C2CC1 QXBFXIKTQCKASH-AAEUAGOBSA-N 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 150000003457 sulfones Chemical group 0.000 claims description 3
- ZMFRTOJDRJYDQC-KGLIPLIRSA-N (5r)-1-[(2s)-2-amino-4-[2-(2-methoxyethyl)-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5-methylpiperidin-2-one Chemical compound C([C@@H](N)CC(=O)N1CC=2N=C(N=C(C=2CC1)C(F)(F)F)CCOC)N1C[C@H](C)CCC1=O ZMFRTOJDRJYDQC-KGLIPLIRSA-N 0.000 claims description 2
- HOZVRGBYSDXNDD-HIFRSBDPSA-N (5r)-1-[(2s)-2-amino-4-[2-(cyclopropylmethyl)-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5-methylpiperidin-2-one Chemical compound C1[C@H](C)CCC(=O)N1C[C@@H](N)CC(=O)N1CC(N=C(CC2CC2)N=C2C(F)(F)F)=C2CC1 HOZVRGBYSDXNDD-HIFRSBDPSA-N 0.000 claims description 2
- ZLQXPIQSMPTOGU-HIFRSBDPSA-N (5r)-1-[(2s)-2-amino-4-[2-cyclobutyl-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5-methylpiperidin-2-one Chemical compound C1[C@H](C)CCC(=O)N1C[C@@H](N)CC(=O)N1CC(N=C(N=C2C(F)(F)F)C3CCC3)=C2CC1 ZLQXPIQSMPTOGU-HIFRSBDPSA-N 0.000 claims description 2
- YOQKDXVRNLVNGR-KGLIPLIRSA-N (5r)-1-[(2s)-2-amino-4-oxo-4-[2-(1h-pyrrol-2-yl)-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]butyl]-5-methylpiperidin-2-one Chemical compound C1[C@H](C)CCC(=O)N1C[C@@H](N)CC(=O)N1CC(N=C(N=C2C(F)(F)F)C=3NC=CC=3)=C2CC1 YOQKDXVRNLVNGR-KGLIPLIRSA-N 0.000 claims description 2
- DIMNCOWKJPBZTI-ZBFHGGJFSA-N (5r)-1-[(2s)-2-amino-4-oxo-4-[2-pyridin-3-yl-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]butyl]-5-methylpiperidin-2-one Chemical compound C1[C@H](C)CCC(=O)N1C[C@@H](N)CC(=O)N1CC(N=C(N=C2C(F)(F)F)C=3C=NC=CC=3)=C2CC1 DIMNCOWKJPBZTI-ZBFHGGJFSA-N 0.000 claims description 2
- RNXARZUJEQCSDC-ZBFHGGJFSA-N (5r)-1-[(2s)-2-amino-4-oxo-4-[2-pyridin-4-yl-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]butyl]-5-methylpiperidin-2-one Chemical compound C1[C@H](C)CCC(=O)N1C[C@@H](N)CC(=O)N1CC(N=C(N=C2C(F)(F)F)C=3C=CN=CC=3)=C2CC1 RNXARZUJEQCSDC-ZBFHGGJFSA-N 0.000 claims description 2
- QQZOPKMRPOGIEB-UHFFFAOYSA-N 2-Oxohexane Chemical compound CCCCC(C)=O QQZOPKMRPOGIEB-UHFFFAOYSA-N 0.000 claims description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 2
- LZXXYWRZDAGXSJ-MNOVXSKESA-N (5r)-1-[(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5-methylpiperidin-2-one Chemical compound C1[C@H](C)CCC(=O)N1C[C@@H](N)CC(=O)N1CC(N=C(N=C2C(F)(F)F)C(F)(F)F)=C2CC1 LZXXYWRZDAGXSJ-MNOVXSKESA-N 0.000 claims 1
- YTHMPIPXDYQIFH-PBHICJAKSA-N (5r)-1-[(2s)-2-amino-4-[2-(4-fluorophenyl)-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5-methylpiperidin-2-one Chemical compound C1[C@H](C)CCC(=O)N1C[C@@H](N)CC(=O)N1CC(N=C(N=C2C(F)(F)F)C=3C=CC(F)=CC=3)=C2CC1 YTHMPIPXDYQIFH-PBHICJAKSA-N 0.000 claims 1
- VTAQGNVTOHRZRK-NEPJUHHUSA-N (5r)-1-[(2s)-2-amino-4-[2-(fluoromethyl)-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5-methylpiperidin-2-one Chemical compound C1[C@H](C)CCC(=O)N1C[C@@H](N)CC(=O)N1CC(N=C(CF)N=C2C(F)(F)F)=C2CC1 VTAQGNVTOHRZRK-NEPJUHHUSA-N 0.000 claims 1
- GYATXFQPZVGGMJ-KGLIPLIRSA-N (5r)-1-[(2s)-2-amino-4-[2-(furan-2-yl)-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5-methylpiperidin-2-one Chemical compound C1[C@H](C)CCC(=O)N1C[C@@H](N)CC(=O)N1CC(N=C(N=C2C(F)(F)F)C=3OC=CC=3)=C2CC1 GYATXFQPZVGGMJ-KGLIPLIRSA-N 0.000 claims 1
- GHNBAWWYZOLGQW-HIFRSBDPSA-N (5r)-1-[(2s)-2-amino-4-[2-(furan-3-yl)-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5-methylpiperidin-2-one Chemical compound C1[C@H](C)CCC(=O)N1C[C@@H](N)CC(=O)N1CC(N=C(N=C2C(F)(F)F)C3=COC=C3)=C2CC1 GHNBAWWYZOLGQW-HIFRSBDPSA-N 0.000 claims 1
- NICJDAWRKKKROW-QAPCUYQASA-N (5r)-1-[(2s)-2-amino-4-[2-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5-methylpiperidin-2-one Chemical compound C1[C@H](C)CCC(=O)N1C[C@@H](N)CC(=O)N1CC(N=C(CC=2C=CC(F)=CC=2)N=C2C(F)(F)F)=C2CC1 NICJDAWRKKKROW-QAPCUYQASA-N 0.000 claims 1
- QVNZWTXNQUSAKF-OLZOCXBDSA-N (5r)-1-[(2s)-2-amino-4-[2-ethyl-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5-methylpiperidin-2-one Chemical compound C([C@@H](N)CC(=O)N1CC=2N=C(N=C(C=2CC1)C(F)(F)F)CC)N1C[C@H](C)CCC1=O QVNZWTXNQUSAKF-OLZOCXBDSA-N 0.000 claims 1
- WALRTZHEUGUMEW-YPMHNXCESA-N (5r)-1-[(2s)-2-amino-4-[2-methyl-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5-methylpiperidin-2-one Chemical compound C1[C@H](C)CCC(=O)N1C[C@@H](N)CC(=O)N1CC(N=C(C)N=C2C(F)(F)F)=C2CC1 WALRTZHEUGUMEW-YPMHNXCESA-N 0.000 claims 1
- XIGSSFWYVCBXNQ-MNOVXSKESA-N (5r)-1-[(2s)-2-amino-4-oxo-4-[2-(1,1,2,2,2-pentafluoroethyl)-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]butyl]-5-methylpiperidin-2-one Chemical compound C1[C@H](C)CCC(=O)N1C[C@@H](N)CC(=O)N1CC(N=C(N=C2C(F)(F)F)C(F)(F)C(F)(F)F)=C2CC1 XIGSSFWYVCBXNQ-MNOVXSKESA-N 0.000 claims 1
- KOARBUHQPKZLHB-WBVHZDCISA-N (5r)-1-[(2s)-2-amino-4-oxo-4-[2-phenyl-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]butyl]-5-methylpiperidin-2-one Chemical compound C1[C@H](C)CCC(=O)N1C[C@@H](N)CC(=O)N1CC(N=C(N=C2C(F)(F)F)C=3C=CC=CC=3)=C2CC1 KOARBUHQPKZLHB-WBVHZDCISA-N 0.000 claims 1
- PTZUFFHRUUTPSB-KGLIPLIRSA-N (5r)-1-[(2s)-2-amino-4-oxo-4-[2-propyl-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]butyl]-5-methylpiperidin-2-one Chemical compound C([C@@H](N)CC(=O)N1CC=2N=C(N=C(C=2CC1)C(F)(F)F)CCC)N1C[C@H](C)CCC1=O PTZUFFHRUUTPSB-KGLIPLIRSA-N 0.000 claims 1
- HVKRQGSOVNNKQT-KGLIPLIRSA-N (5r)-1-[(2s)-2-amino-4-oxo-4-[2-thiophen-2-yl-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]butyl]-5-methylpiperidin-2-one Chemical compound C1[C@H](C)CCC(=O)N1C[C@@H](N)CC(=O)N1CC(N=C(N=C2C(F)(F)F)C=3SC=CC=3)=C2CC1 HVKRQGSOVNNKQT-KGLIPLIRSA-N 0.000 claims 1
- QTXOAUMQCVDJGC-HIFRSBDPSA-N (5r)-1-[(2s)-2-amino-4-oxo-4-[2-thiophen-3-yl-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]butyl]-5-methylpiperidin-2-one Chemical compound C1[C@H](C)CCC(=O)N1C[C@@H](N)CC(=O)N1CC(N=C(N=C2C(F)(F)F)C3=CSC=C3)=C2CC1 QTXOAUMQCVDJGC-HIFRSBDPSA-N 0.000 claims 1
- LZXXYWRZDAGXSJ-QWRGUYRKSA-N (5s)-1-[(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5-methylpiperidin-2-one Chemical compound C1[C@@H](C)CCC(=O)N1C[C@@H](N)CC(=O)N1CC(N=C(N=C2C(F)(F)F)C(F)(F)F)=C2CC1 LZXXYWRZDAGXSJ-QWRGUYRKSA-N 0.000 claims 1
- UOBNYVYEPQSIGK-BBRMVZONSA-N (6s)-4-[(2s)-2-amino-4-[2-(3-fluorophenyl)-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-6-methylmorpholin-3-one Chemical compound O=C1CO[C@@H](C)CN1C[C@@H](N)CC(=O)N1CC(N=C(N=C2C(F)(F)F)C=3C=C(F)C=CC=3)=C2CC1 UOBNYVYEPQSIGK-BBRMVZONSA-N 0.000 claims 1
- VDKVOKNVOQJFHM-BBRMVZONSA-N (6s)-4-[(2s)-2-amino-4-[2-(4-fluorophenyl)-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-6-methylmorpholin-2-one Chemical compound C1C(=O)O[C@@H](C)CN1C[C@@H](N)CC(=O)N1CC(N=C(N=C2C(F)(F)F)C=3C=CC(F)=CC=3)=C2CC1 VDKVOKNVOQJFHM-BBRMVZONSA-N 0.000 claims 1
- XALIVERBROSNTF-ZFWWWQNUSA-N (6s)-4-[(2s)-2-amino-4-[2-cyclopentyl-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-6-methylmorpholin-3-one Chemical compound O=C1CO[C@@H](C)CN1C[C@@H](N)CC(=O)N1CC(N=C(N=C2C(F)(F)F)C3CCCC3)=C2CC1 XALIVERBROSNTF-ZFWWWQNUSA-N 0.000 claims 1
- AXWDXONSVHXTBM-RYUDHWBXSA-N (6s)-4-[(2s)-2-amino-4-[2-ethyl-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-6-methylmorpholin-3-one Chemical compound C([C@@H](N)CC(=O)N1CC=2N=C(N=C(C=2CC1)C(F)(F)F)CC)N1C[C@H](C)OCC1=O AXWDXONSVHXTBM-RYUDHWBXSA-N 0.000 claims 1
- IZJNAQGFGRUTAK-JQWIXIFHSA-N (6s)-4-[(2s)-2-amino-4-[2-methyl-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-6-methylmorpholin-3-one Chemical compound O=C1CO[C@@H](C)CN1C[C@@H](N)CC(=O)N1CC(N=C(C)N=C2C(F)(F)F)=C2CC1 IZJNAQGFGRUTAK-JQWIXIFHSA-N 0.000 claims 1
- HXXZPZJQBSVVEH-UWVGGRQHSA-N (6s)-4-[(2s)-2-amino-4-oxo-4-[2-(1,1,2,2,2-pentafluoroethyl)-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]butyl]-6-methylmorpholin-3-one Chemical compound O=C1CO[C@@H](C)CN1C[C@@H](N)CC(=O)N1CC(N=C(N=C2C(F)(F)F)C(F)(F)C(F)(F)F)=C2CC1 HXXZPZJQBSVVEH-UWVGGRQHSA-N 0.000 claims 1
- RGUKLINDNPENJG-HOCLYGCPSA-N (6s)-4-[(2s)-2-amino-4-oxo-4-[2-phenyl-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]butyl]-6-methylmorpholin-3-one Chemical compound O=C1CO[C@@H](C)CN1C[C@@H](N)CC(=O)N1CC(N=C(N=C2C(F)(F)F)C=3C=CC=CC=3)=C2CC1 RGUKLINDNPENJG-HOCLYGCPSA-N 0.000 claims 1
- XOLQWYLLPCJCFL-STQMWFEESA-N (6s)-4-[(2s)-2-amino-4-oxo-4-[2-propan-2-yl-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]butyl]-6-methylmorpholin-3-one Chemical compound C([C@@H](N)CC(=O)N1CC=2N=C(N=C(C=2CC1)C(F)(F)F)C(C)C)N1C[C@H](C)OCC1=O XOLQWYLLPCJCFL-STQMWFEESA-N 0.000 claims 1
- IMRAAOZIDILJHR-QWRGUYRKSA-N (6s)-4-[(2s)-2-amino-4-oxo-4-[4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]butyl]-6-methylmorpholin-3-one Chemical compound O=C1CO[C@@H](C)CN1C[C@@H](N)CC(=O)N1CC(N=CN=C2C(F)(F)F)=C2CC1 IMRAAOZIDILJHR-QWRGUYRKSA-N 0.000 claims 1
- DNWVHQFBVOEHFO-JSGCOSHPSA-N (6s)-4-[(2s)-2-amino-4-oxo-4-[5-(trifluoromethyl)-3,4-dihydro-1h-isoquinolin-2-yl]butyl]-6-methylmorpholin-3-one Chemical compound O=C1CO[C@@H](C)CN1C[C@@H](N)CC(=O)N1CC(C=CC=C2C(F)(F)F)=C2CC1 DNWVHQFBVOEHFO-JSGCOSHPSA-N 0.000 claims 1
- VCLHTXJUNLKZBG-JTQLQIEISA-N 1-[(2s)-2-amino-4-oxo-4-[4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]butyl]-5,5-difluoropiperidin-2-one Chemical compound C([C@@H](N)CC(=O)N1CC2=C(C(=NC=N2)C(F)(F)F)CC1)N1CC(F)(F)CCC1=O VCLHTXJUNLKZBG-JTQLQIEISA-N 0.000 claims 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 description 772
- 230000015572 biosynthetic process Effects 0.000 description 445
- 238000003786 synthesis reaction Methods 0.000 description 445
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 390
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 304
- 238000005481 NMR spectroscopy Methods 0.000 description 278
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 256
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 213
- 238000005160 1H NMR spectroscopy Methods 0.000 description 194
- 239000000243 solution Substances 0.000 description 153
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 132
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 108
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 106
- 238000006243 chemical reaction Methods 0.000 description 101
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 99
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 96
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 84
- 239000002253 acid Substances 0.000 description 76
- 229940093499 ethyl acetate Drugs 0.000 description 70
- 235000019439 ethyl acetate Nutrition 0.000 description 70
- 238000003756 stirring Methods 0.000 description 67
- 239000000047 product Substances 0.000 description 62
- 238000004440 column chromatography Methods 0.000 description 60
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 42
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 41
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 38
- 239000002904 solvent Substances 0.000 description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 29
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 29
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 27
- 239000012044 organic layer Substances 0.000 description 27
- IDXKTTNFXPPXJY-UHFFFAOYSA-N pyrimidin-1-ium;chloride Chemical compound Cl.C1=CN=CN=C1 IDXKTTNFXPPXJY-UHFFFAOYSA-N 0.000 description 26
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 25
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 20
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 19
- 239000003112 inhibitor Substances 0.000 description 19
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 19
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 16
- HHWQLKZXKQDPLH-UHFFFAOYSA-N 3-oxo-4-(2,2,2-trifluoroacetyl)piperidine-1-carboxylic acid Chemical compound OC(=O)N1CCC(C(=O)C(F)(F)F)C(=O)C1 HHWQLKZXKQDPLH-UHFFFAOYSA-N 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 239000011734 sodium Substances 0.000 description 14
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 11
- FUHZEIWXMXDMSS-UHFFFAOYSA-N tert-butyl 3-oxo-4-(2,2,2-trifluoroacetyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C(=O)C(F)(F)F)C(=O)C1 FUHZEIWXMXDMSS-UHFFFAOYSA-N 0.000 description 11
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 10
- NFEZOYIKZXDOAJ-UHFFFAOYSA-N 2,4-bis(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C1NCCC2=C1N=C(C(F)(F)F)N=C2C(F)(F)F NFEZOYIKZXDOAJ-UHFFFAOYSA-N 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 235000019270 ammonium chloride Nutrition 0.000 description 10
- 229940093858 ethyl acetoacetate Drugs 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 150000001412 amines Chemical class 0.000 description 9
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 125000006242 amine protecting group Chemical group 0.000 description 8
- 238000004821 distillation Methods 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- SEJCUJPNYNEKKA-UHFFFAOYSA-N 2-(furan-3-yl)-4-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.N=1C=2CNCCC=2C(C(F)(F)F)=NC=1C=1C=COC=1 SEJCUJPNYNEKKA-UHFFFAOYSA-N 0.000 description 6
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 229960001866 silicon dioxide Drugs 0.000 description 6
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 229960004132 diethyl ether Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- JNODQFNWMXFMEV-UHFFFAOYSA-N latrepirdine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 description 5
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 5
- LUQURLQDYAJECW-UHFFFAOYSA-N tert-butyl 3-amino-4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)C(N)C1 LUQURLQDYAJECW-UHFFFAOYSA-N 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 4
- GJFJDKALAUIPSO-UHFFFAOYSA-N methyl 5-amino-4,4-difluoropentanoate;hydrochloride Chemical compound Cl.COC(=O)CCC(F)(F)CN GJFJDKALAUIPSO-UHFFFAOYSA-N 0.000 description 4
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- WOCIAKWEIIZHES-UHFFFAOYSA-N ruthenium(iv) oxide Chemical compound O=[Ru]=O WOCIAKWEIIZHES-UHFFFAOYSA-N 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 3
- FNSWQYZNZFCUOO-UHFFFAOYSA-N 2-(1,1,2,2,2-pentafluoroethyl)-4-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C1NCCC2=C1N=C(C(F)(F)C(F)(F)F)N=C2C(F)(F)F FNSWQYZNZFCUOO-UHFFFAOYSA-N 0.000 description 3
- WHBWGLNMQXUTJB-UHFFFAOYSA-N 2-(3,4-difluorophenyl)-4-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C1=C(F)C(F)=CC=C1C(N=C1C(F)(F)F)=NC2=C1CCNC2 WHBWGLNMQXUTJB-UHFFFAOYSA-N 0.000 description 3
- VPWTXWWRMYIFOM-UHFFFAOYSA-N 2-(4-fluorophenyl)-4-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C1=CC(F)=CC=C1C(N=C1C(F)(F)F)=NC2=C1CCNC2 VPWTXWWRMYIFOM-UHFFFAOYSA-N 0.000 description 3
- XBLNPVMPVFYCJY-UHFFFAOYSA-N 2-cyclopentyl-4-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.N=1C=2CNCCC=2C(C(F)(F)F)=NC=1C1CCCC1 XBLNPVMPVFYCJY-UHFFFAOYSA-N 0.000 description 3
- QDKIRCFWCJSTHW-UHFFFAOYSA-N 2-cyclopropyl-4-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.N=1C=2CNCCC=2C(C(F)(F)F)=NC=1C1CC1 QDKIRCFWCJSTHW-UHFFFAOYSA-N 0.000 description 3
- QDKGGUVUUBZSOR-UHFFFAOYSA-N 2-cyclopropylethanimidamide Chemical compound NC(=N)CC1CC1 QDKGGUVUUBZSOR-UHFFFAOYSA-N 0.000 description 3
- OZNWRLZWYGELDT-UHFFFAOYSA-N 2-ethyl-4-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C1NCCC2=C1N=C(CC)N=C2C(F)(F)F OZNWRLZWYGELDT-UHFFFAOYSA-N 0.000 description 3
- HAIYEFMGUXOXIY-UHFFFAOYSA-N 2-fluoroethanimidamide Chemical compound NC(=N)CF HAIYEFMGUXOXIY-UHFFFAOYSA-N 0.000 description 3
- VPZTZKMLUSCNNK-UHFFFAOYSA-N 2-methyl-4-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C1NCCC2=C1N=C(C)N=C2C(F)(F)F VPZTZKMLUSCNNK-UHFFFAOYSA-N 0.000 description 3
- NDAJNMAAXXIADY-UHFFFAOYSA-N 2-methylpropanimidamide Chemical compound CC(C)C(N)=N NDAJNMAAXXIADY-UHFFFAOYSA-N 0.000 description 3
- YDMSEGANCOBECN-UHFFFAOYSA-N 2-phenyl-4-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.N=1C=2CNCCC=2C(C(F)(F)F)=NC=1C1=CC=CC=C1 YDMSEGANCOBECN-UHFFFAOYSA-N 0.000 description 3
- HBJFGRUEURBJEF-UHFFFAOYSA-N 2-propan-2-yl-4-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C1NCCC2=C1N=C(C(C)C)N=C2C(F)(F)F HBJFGRUEURBJEF-UHFFFAOYSA-N 0.000 description 3
- XMTDDZPNGYMWHQ-UHFFFAOYSA-N 4-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C1NCCC2=C1N=CN=C2C(F)(F)F XMTDDZPNGYMWHQ-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- RXKUYBRRTKRGME-UHFFFAOYSA-N butanimidamide Chemical compound CCCC(N)=N RXKUYBRRTKRGME-UHFFFAOYSA-N 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- KHVUTUHWRKYNPL-SECBINFHSA-N ethyl 2-[(2r)-1-[(2-methylpropan-2-yl)oxycarbonylamino]propan-2-yl]oxyacetate Chemical compound CCOC(=O)CO[C@H](C)CNC(=O)OC(C)(C)C KHVUTUHWRKYNPL-SECBINFHSA-N 0.000 description 3
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 3
- SUYLXDVVMSCSFK-UHFFFAOYSA-N ethyl 3-(aminomethyl)-4,4,4-trifluorobutanoate;hydrochloride Chemical compound Cl.CCOC(=O)CC(CN)C(F)(F)F SUYLXDVVMSCSFK-UHFFFAOYSA-N 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 150000003951 lactams Chemical group 0.000 description 3
- HHFAFLPJRXUFJK-RXMQYKEDSA-N methyl (2r)-2-methyl-3-methylsulfonyloxypropanoate Chemical compound COC(=O)[C@H](C)COS(C)(=O)=O HHFAFLPJRXUFJK-RXMQYKEDSA-N 0.000 description 3
- LHOFUYMABMHQEY-VIFPVBQESA-N methyl (4s)-4-methyl-5-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate Chemical compound COC(=O)CC[C@H](C)CNC(=O)OC(C)(C)C LHOFUYMABMHQEY-VIFPVBQESA-N 0.000 description 3
- LBMJWEDXCGGVJU-RGMNGODLSA-N methyl (4s)-5-amino-4-methylpentanoate;hydrochloride Chemical compound Cl.COC(=O)CC[C@H](C)CN LBMJWEDXCGGVJU-RGMNGODLSA-N 0.000 description 3
- GKRPURFPTFWNBW-UHFFFAOYSA-N methyl 4-(aminomethyl)-5,5,5-trifluoropentanoate;hydrochloride Chemical compound Cl.COC(=O)CCC(CN)C(F)(F)F GKRPURFPTFWNBW-UHFFFAOYSA-N 0.000 description 3
- JZQUSBLVXXPBSF-UHFFFAOYSA-N methyl 4-[hydroxy-[(2-methylpropan-2-yl)oxycarbonyl]amino]-3,3-dimethylbutanoate Chemical compound COC(=O)CC(C)(C)CN(O)C(=O)OC(C)(C)C JZQUSBLVXXPBSF-UHFFFAOYSA-N 0.000 description 3
- BWZXQJZZCYZRKU-UHFFFAOYSA-N methyl 4-amino-3-methylbut-2-enoate hydrochloride Chemical compound Cl.COC(=O)C=C(C)CN BWZXQJZZCYZRKU-UHFFFAOYSA-N 0.000 description 3
- QJNCFUKXJGODQX-UHFFFAOYSA-N methyl 5-amino-3-methylpentanoate;hydrochloride Chemical compound Cl.COC(=O)CC(C)CCN QJNCFUKXJGODQX-UHFFFAOYSA-N 0.000 description 3
- FAKIZCQRTPAOSH-UHFFFAOYSA-N methyl 5-aminopentanoate;hydrochloride Chemical compound Cl.COC(=O)CCCCN FAKIZCQRTPAOSH-UHFFFAOYSA-N 0.000 description 3
- XITQUSLLOSKDTB-UHFFFAOYSA-N nitrofen Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC1=CC=C(Cl)C=C1Cl XITQUSLLOSKDTB-UHFFFAOYSA-N 0.000 description 3
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 3
- BIJRUEBMNUUNIJ-UHFFFAOYSA-N pyridine-4-carboximidamide Chemical compound NC(=N)C1=CC=NC=C1 BIJRUEBMNUUNIJ-UHFFFAOYSA-N 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- JKCKRNYECSTMLV-UHFFFAOYSA-N thiophene-3-carboximidamide Chemical compound NC(=N)C=1C=CSC=1 JKCKRNYECSTMLV-UHFFFAOYSA-N 0.000 description 3
- MXLLYTNXXYRRFX-AXDSSHIGSA-N (3s)-3-[(2-methylpropan-2-yl)oxycarbonylamino]-4-[2-oxo-5-(trifluoromethyl)piperidin-1-yl]butanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](CC(O)=O)CN1CC(C(F)(F)F)CCC1=O MXLLYTNXXYRRFX-AXDSSHIGSA-N 0.000 description 2
- QYTRYTQNQKXPRC-JSGCOSHPSA-N (6s)-4-[(2s)-2-amino-4-[2-(3,4-difluorophenyl)-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-6-methylmorpholin-3-one Chemical compound O=C1CO[C@@H](C)CN1C[C@@H](N)CC(=O)N1CC(N=C(N=C2C(F)(F)F)C=3C=C(F)C(F)=CC=3)=C2CC1 QYTRYTQNQKXPRC-JSGCOSHPSA-N 0.000 description 2
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 2
- BDFBWUCKZPJKOJ-UHFFFAOYSA-N 2-(3-fluorophenyl)-4-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.FC1=CC=CC(C=2N=C(C=3CCNCC=3N=2)C(F)(F)F)=C1 BDFBWUCKZPJKOJ-UHFFFAOYSA-N 0.000 description 2
- LBMVNBZGHAZJNN-UHFFFAOYSA-N 2-(4-fluorophenyl)ethanimidamide Chemical compound NC(=N)CC1=CC=C(F)C=C1 LBMVNBZGHAZJNN-UHFFFAOYSA-N 0.000 description 2
- XSCUABVRTJJVBK-UHFFFAOYSA-N 2-(cyclopropylmethyl)-4-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.N=1C=2CNCCC=2C(C(F)(F)F)=NC=1CC1CC1 XSCUABVRTJJVBK-UHFFFAOYSA-N 0.000 description 2
- WONZEIFUBJUNCF-UHFFFAOYSA-N 2-(fluoromethyl)-4-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C1NCCC2=C1N=C(CF)N=C2C(F)(F)F WONZEIFUBJUNCF-UHFFFAOYSA-N 0.000 description 2
- AOZRNHRUQHDJEV-UHFFFAOYSA-N 2-(furan-2-yl)-4-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.N=1C=2CNCCC=2C(C(F)(F)F)=NC=1C1=CC=CO1 AOZRNHRUQHDJEV-UHFFFAOYSA-N 0.000 description 2
- BHHPERGUGRXUPR-UHFFFAOYSA-N 2-[(4-fluorophenyl)methyl]-4-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C1=CC(F)=CC=C1CC(N=C1C(F)(F)F)=NC2=C1CCNC2 BHHPERGUGRXUPR-UHFFFAOYSA-N 0.000 description 2
- CUTAUIDZDOAALR-UHFFFAOYSA-N 2-[4-(trifluoromethyl)phenyl]-4,5,6,7-tetrahydro-[1,3]thiazolo[4,5-c]pyridine Chemical compound C1=CC(C(F)(F)F)=CC=C1C(S1)=NC2=C1CCNC2 CUTAUIDZDOAALR-UHFFFAOYSA-N 0.000 description 2
- FMMPSFVUCINYSB-UHFFFAOYSA-N 2-cyclobutyl-4-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.N=1C=2CNCCC=2C(C(F)(F)F)=NC=1C1CCC1 FMMPSFVUCINYSB-UHFFFAOYSA-N 0.000 description 2
- ZGWXNEPNAFZSAC-UHFFFAOYSA-N 2-oxo-5-(trifluoromethyl)piperidine-1-carboxylic acid Chemical compound OC(=O)N1CC(C(F)(F)F)CCC1=O ZGWXNEPNAFZSAC-UHFFFAOYSA-N 0.000 description 2
- GHLNIZZYPKNSBZ-UHFFFAOYSA-N 2-propyl-4-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C1NCCC2=C1N=C(CCC)N=C2C(F)(F)F GHLNIZZYPKNSBZ-UHFFFAOYSA-N 0.000 description 2
- IEKQODUGQZGECP-UHFFFAOYSA-N 2-pyridin-4-yl-4-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.N=1C=2CNCCC=2C(C(F)(F)F)=NC=1C1=CC=NC=C1 IEKQODUGQZGECP-UHFFFAOYSA-N 0.000 description 2
- ZVIDEVZZPXBEET-UHFFFAOYSA-N 2-tert-butyl-4-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C1NCCC2=C1N=C(C(C)(C)C)N=C2C(F)(F)F ZVIDEVZZPXBEET-UHFFFAOYSA-N 0.000 description 2
- ZOTVJTIACSPFDI-UHFFFAOYSA-N 2-thiophen-2-yl-4-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.N=1C=2CNCCC=2C(C(F)(F)F)=NC=1C1=CC=CS1 ZOTVJTIACSPFDI-UHFFFAOYSA-N 0.000 description 2
- VGQBRRJBRWTVRX-UHFFFAOYSA-N 2-thiophen-3-yl-4-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.N=1C=2CNCCC=2C(C(F)(F)F)=NC=1C=1C=CSC=1 VGQBRRJBRWTVRX-UHFFFAOYSA-N 0.000 description 2
- KJGLNSUZZDFEKU-UHFFFAOYSA-N 3-(1,1,2,2,2-pentafluoroethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine Chemical compound C1=NCCN2C(C(F)(F)C(F)(F)F)=NN=C21 KJGLNSUZZDFEKU-UHFFFAOYSA-N 0.000 description 2
- FMTDZGCPYKWMPT-UHFFFAOYSA-N 3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine Chemical compound C1NCCN2C(C(F)(F)F)=NN=C21 FMTDZGCPYKWMPT-UHFFFAOYSA-N 0.000 description 2
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
- SOYGDYKLWFRCGI-UHFFFAOYSA-N 3-fluorobenzenecarboximidamide Chemical compound NC(=N)C1=CC=CC(F)=C1 SOYGDYKLWFRCGI-UHFFFAOYSA-N 0.000 description 2
- GOLODWMXGLKPFT-UHFFFAOYSA-N 3-methoxypropanimidamide Chemical compound COCCC(N)=N GOLODWMXGLKPFT-UHFFFAOYSA-N 0.000 description 2
- MSHFRERJPWKJFX-UHFFFAOYSA-N 4-Methoxybenzyl alcohol Chemical compound COC1=CC=C(CO)C=C1 MSHFRERJPWKJFX-UHFFFAOYSA-N 0.000 description 2
- OSTGTIZRQZOYAH-UHFFFAOYSA-N 4-fluorobenzenecarboximidamide Chemical compound NC(=N)C1=CC=C(F)C=C1 OSTGTIZRQZOYAH-UHFFFAOYSA-N 0.000 description 2
- FEFGEIVSLKAPEG-UHFFFAOYSA-N 4-methyl-2-oxopiperidine-1-carboxylic acid Chemical compound CC1CCN(C(O)=O)C(=O)C1 FEFGEIVSLKAPEG-UHFFFAOYSA-N 0.000 description 2
- VIRFRHVDXNAETH-UHFFFAOYSA-N 4-methylpiperidine-1-carboxylic acid Chemical compound CC1CCN(C(O)=O)CC1 VIRFRHVDXNAETH-UHFFFAOYSA-N 0.000 description 2
- YRKCLUZAQCBIII-UHFFFAOYSA-N 5-(trifluoromethyl)piperidin-2-one Chemical compound FC(F)(F)C1CCC(=O)NC1 YRKCLUZAQCBIII-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000872931 Myoporum sandwicense Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- FJPJVFDVXVNGOF-GSVOUGTGSA-N [(2r)-2-hydroxypropyl]carbamic acid Chemical compound C[C@@H](O)CNC(O)=O FJPJVFDVXVNGOF-GSVOUGTGSA-N 0.000 description 2
- VTVYTFMCINHIAG-SCSAIBSYSA-N [(2r)-3-hydroxy-2-methylpropyl]carbamic acid Chemical compound OC[C@H](C)CNC(O)=O VTVYTFMCINHIAG-SCSAIBSYSA-N 0.000 description 2
- VTVYTFMCINHIAG-BYPYZUCNSA-N [(2s)-3-hydroxy-2-methylpropyl]carbamic acid Chemical compound OC[C@@H](C)CNC(O)=O VTVYTFMCINHIAG-BYPYZUCNSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001721 carbon Chemical class 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 229960004424 carbon dioxide Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 150000004292 cyclic ethers Chemical class 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- QPRVVHRECABHRN-UHFFFAOYSA-N ethyl 4,4,4-trifluoro-3-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]butanoate Chemical compound CCOC(=O)CC(C(F)(F)F)CNC(=O)OC(C)(C)C QPRVVHRECABHRN-UHFFFAOYSA-N 0.000 description 2
- AUQSQPFSXLNYOQ-UHFFFAOYSA-N ethyl 4,4,4-trifluoro-3-[[hydroxy-[(2-methylpropan-2-yl)oxycarbonyl]amino]methyl]butanoate Chemical compound CCOC(=O)CC(C(F)(F)F)CN(O)C(=O)OC(C)(C)C AUQSQPFSXLNYOQ-UHFFFAOYSA-N 0.000 description 2
- RTSDUVUCQZUYKZ-UHFFFAOYSA-N ethyl 5-amino-3-(trifluoromethyl)pentanoate;hydrochloride Chemical compound Cl.CCOC(=O)CC(C(F)(F)F)CCN RTSDUVUCQZUYKZ-UHFFFAOYSA-N 0.000 description 2
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- YVPJCJLMRRTDMQ-UHFFFAOYSA-N ethyl diazoacetate Chemical compound CCOC(=O)C=[N+]=[N-] YVPJCJLMRRTDMQ-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- FUVVSNUVSKUJAS-UHFFFAOYSA-N furan-2-carboximidamide Chemical compound NC(=N)C1=CC=CO1 FUVVSNUVSKUJAS-UHFFFAOYSA-N 0.000 description 2
- NPTVCIGQICWSLH-UHFFFAOYSA-N furan-3-carboximidamide Chemical compound NC(=N)C=1C=COC=1 NPTVCIGQICWSLH-UHFFFAOYSA-N 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- HHFAFLPJRXUFJK-YFKPBYRVSA-N methyl (2s)-2-methyl-3-methylsulfonyloxypropanoate Chemical compound COC(=O)[C@@H](C)COS(C)(=O)=O HHFAFLPJRXUFJK-YFKPBYRVSA-N 0.000 description 2
- UIJPNDQJMMBMCW-SECBINFHSA-N methyl (4r)-4-methyl-5-[(2-methylpropan-2-yl)oxycarbonylamino]pent-2-enoate Chemical compound COC(=O)C=C[C@@H](C)CNC(=O)OC(C)(C)C UIJPNDQJMMBMCW-SECBINFHSA-N 0.000 description 2
- LBMJWEDXCGGVJU-FYZOBXCZSA-N methyl (4r)-5-amino-4-methylpentanoate;hydrochloride Chemical compound Cl.COC(=O)CC[C@@H](C)CN LBMJWEDXCGGVJU-FYZOBXCZSA-N 0.000 description 2
- WOIHOEYFYQOGKO-UHFFFAOYSA-N methyl 2-fluoro-4-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate Chemical compound COC(=O)C(F)CCNC(=O)OC(C)(C)C WOIHOEYFYQOGKO-UHFFFAOYSA-N 0.000 description 2
- IFVSMOFKYPXOSR-UHFFFAOYSA-N methyl 2-fluoro-5-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate Chemical compound COC(=O)C(F)CCCNC(=O)OC(C)(C)C IFVSMOFKYPXOSR-UHFFFAOYSA-N 0.000 description 2
- WFJCATDYIVQSSJ-UHFFFAOYSA-N methyl 2-methyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate Chemical compound COC(=O)C(C)CCNC(=O)OC(C)(C)C WFJCATDYIVQSSJ-UHFFFAOYSA-N 0.000 description 2
- CBSWQPBHPCWSAX-UHFFFAOYSA-N methyl 3-methyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate Chemical compound COC(=O)CC(C)CNC(=O)OC(C)(C)C CBSWQPBHPCWSAX-UHFFFAOYSA-N 0.000 description 2
- DZQJCNUWYDGVCF-UHFFFAOYSA-N methyl 3-methyl-4-nitrobutanoate Chemical compound COC(=O)CC(C)C[N+]([O-])=O DZQJCNUWYDGVCF-UHFFFAOYSA-N 0.000 description 2
- UFSRLPPZCKEGEH-UHFFFAOYSA-N methyl 3-methyl-5-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate Chemical compound COC(=O)CC(C)CCNC(=O)OC(C)(C)C UFSRLPPZCKEGEH-UHFFFAOYSA-N 0.000 description 2
- QZVBHEXOPNCGFZ-UHFFFAOYSA-N methyl 4,4-difluoro-5-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate Chemical compound COC(=O)CCC(F)(F)CNC(=O)OC(C)(C)C QZVBHEXOPNCGFZ-UHFFFAOYSA-N 0.000 description 2
- BSLQTOGBQTWQGZ-UHFFFAOYSA-N methyl 4-[bis[(2-methylpropan-2-yl)oxycarbonyl]amino]-2-hydroxy-3,3-dimethylbutanoate Chemical compound COC(=O)C(O)C(C)(C)CN(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C BSLQTOGBQTWQGZ-UHFFFAOYSA-N 0.000 description 2
- RSENCDQCULGKMU-UHFFFAOYSA-N methyl 4-amino-2-methylbutanoate;hydrochloride Chemical compound Cl.COC(=O)C(C)CCN RSENCDQCULGKMU-UHFFFAOYSA-N 0.000 description 2
- XMTSNVMIKXQAPW-UHFFFAOYSA-N methyl 4-amino-3-methylbutanoate Chemical compound COC(=O)CC(C)CN XMTSNVMIKXQAPW-UHFFFAOYSA-N 0.000 description 2
- ISARYZPDAVBWAR-UHFFFAOYSA-N methyl 4-amino-3-methylbutanoate;hydrochloride Chemical compound Cl.COC(=O)CC(C)CN ISARYZPDAVBWAR-UHFFFAOYSA-N 0.000 description 2
- YHIYMUOXGLYETF-UHFFFAOYSA-N methyl 5-amino-2-fluoropentanoate;hydrochloride Chemical compound Cl.COC(=O)C(F)CCCN YHIYMUOXGLYETF-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- FTNFEHXDETWERN-UHFFFAOYSA-N n-[bis(aziridin-1-yl)phosphoryl]-2,6-dimethyl-5-[(4-propan-2-yloxyphenyl)methyl]pyrimidin-4-amine Chemical compound C1=CC(OC(C)C)=CC=C1CC1=C(C)N=C(C)N=C1NP(=O)(N1CC1)N1CC1 FTNFEHXDETWERN-UHFFFAOYSA-N 0.000 description 2
- XHXVAJHZTIXQQD-UHFFFAOYSA-N n-[bis(aziridin-1-yl)phosphoryl]-5-[(4-butoxyphenyl)methyl]-2,6-dimethylpyrimidin-4-amine Chemical compound C1=CC(OCCCC)=CC=C1CC1=C(C)N=C(C)N=C1NP(=O)(N1CC1)N1CC1 XHXVAJHZTIXQQD-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003138 primary alcohols Chemical class 0.000 description 2
- GNFWGDKKNWGGJY-UHFFFAOYSA-N propanimidamide Chemical compound CCC(N)=N GNFWGDKKNWGGJY-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- SVOOVMQUISJERI-UHFFFAOYSA-K rhodium(3+);triacetate Chemical compound [Rh+3].CC([O-])=O.CC([O-])=O.CC([O-])=O SVOOVMQUISJERI-UHFFFAOYSA-K 0.000 description 2
- ATCCIZURPPEVIZ-SCSAIBSYSA-N roche ester Chemical compound COC(=O)[C@H](C)CO ATCCIZURPPEVIZ-SCSAIBSYSA-N 0.000 description 2
- 229910001925 ruthenium oxide Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- YNJCFDAODGKHAV-UHFFFAOYSA-N tert-butyl n-(2-hydroxypropyl)carbamate Chemical compound CC(O)CNC(=O)OC(C)(C)C YNJCFDAODGKHAV-UHFFFAOYSA-N 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical group CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical group [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Substances C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-ZETCQYMHSA-N (1S)-1-phenylethanamine Chemical compound C[C@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-ZETCQYMHSA-N 0.000 description 1
- HXKKHQJGJAFBHI-GSVOUGTGSA-N (2R)-1-aminopropan-2-ol Chemical compound C[C@@H](O)CN HXKKHQJGJAFBHI-GSVOUGTGSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- HXKKHQJGJAFBHI-VKHMYHEASA-N (2s)-1-aminopropan-2-ol Chemical compound C[C@H](O)CN HXKKHQJGJAFBHI-VKHMYHEASA-N 0.000 description 1
- YOYRVVRVDDHIJL-AXDSSHIGSA-N (3S)-4-(4-methyl-2,3-dioxopiperidin-1-yl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC1CCN(C[C@H](CC(O)=O)NC(=O)OC(C)(C)C)C(=O)C1=O YOYRVVRVDDHIJL-AXDSSHIGSA-N 0.000 description 1
- NYFSYIFADKELCR-VIFPVBQESA-N (3s)-4-(5,5-difluoro-2-oxopiperidin-1-yl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](CC(O)=O)CN1CC(F)(F)CCC1=O NYFSYIFADKELCR-VIFPVBQESA-N 0.000 description 1
- TUXLUMNQLZVDGM-MNOVXSKESA-N (3s)-4-[(5r)-5-methyl-2-oxopiperidin-1-yl]-3-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound C[C@@H]1CCC(=O)N(C[C@H](CC(O)=O)NC(=O)OC(C)(C)C)C1 TUXLUMNQLZVDGM-MNOVXSKESA-N 0.000 description 1
- PSNUVGIVZCOHME-RXMQYKEDSA-N (4r)-5-amino-4-methylpentanoic acid Chemical compound NC[C@H](C)CCC(O)=O PSNUVGIVZCOHME-RXMQYKEDSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- AKCVBCRPNQCGNB-UHFFFAOYSA-N 1-hydroxy-2h-pyridine-2,3,6-triol Chemical compound OC1N(O)C(O)=CC=C1O AKCVBCRPNQCGNB-UHFFFAOYSA-N 0.000 description 1
- NITMACBPVVUGOJ-UHFFFAOYSA-N 2,2,2-trifluoroethanimidamide Chemical compound NC(=N)C(F)(F)F NITMACBPVVUGOJ-UHFFFAOYSA-N 0.000 description 1
- FNHMJTUQUPQWJN-UHFFFAOYSA-N 2,2-dimethylpropanimidamide Chemical compound CC(C)(C)C(N)=N FNHMJTUQUPQWJN-UHFFFAOYSA-N 0.000 description 1
- GEYVRSNZPVNVRL-UHFFFAOYSA-N 2,4-bis(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxylic acid Chemical compound N1=C(C(F)(F)F)N=C(C(F)(F)F)C2=C1CN(C(=O)O)CC2 GEYVRSNZPVNVRL-UHFFFAOYSA-N 0.000 description 1
- ZXSJGVCFJKJGTA-UHFFFAOYSA-N 2-(2-methoxyethyl)-4-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine Chemical compound C1NCCC2=C1N=C(CCOC)N=C2C(F)(F)F ZXSJGVCFJKJGTA-UHFFFAOYSA-N 0.000 description 1
- CVDBARKNJALARX-UHFFFAOYSA-N 2-(2-methoxyethyl)-4-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.C1NCCC2=C1N=C(CCOC)N=C2C(F)(F)F CVDBARKNJALARX-UHFFFAOYSA-N 0.000 description 1
- JHQBLYITVCBGTO-UHFFFAOYSA-N 2-(4-fluorophenyl)acetonitrile Chemical compound FC1=CC=C(CC#N)C=C1 JHQBLYITVCBGTO-UHFFFAOYSA-N 0.000 description 1
- MTPYEABPEQXNCO-UHFFFAOYSA-N 2-(furan-2-yl)-4-(trifluoromethyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylic acid Chemical compound C1N(C(=O)O)CCC(C(=N2)C(F)(F)F)=C1N=C2C1=CC=CO1 MTPYEABPEQXNCO-UHFFFAOYSA-N 0.000 description 1
- XJICBENVKDPGAI-UHFFFAOYSA-N 2-(furan-3-yl)-4-(trifluoromethyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylic acid Chemical compound C1N(C(=O)O)CCC(C(=N2)C(F)(F)F)=C1N=C2C=1C=COC=1 XJICBENVKDPGAI-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FBPINGSGHKXIQA-UHFFFAOYSA-N 2-amino-3-(2-carboxyethylsulfanyl)propanoic acid Chemical compound OC(=O)C(N)CSCCC(O)=O FBPINGSGHKXIQA-UHFFFAOYSA-N 0.000 description 1
- FAUQRRGKJKMEIW-UHFFFAOYSA-N 2-cyclopropylacetonitrile Chemical compound N#CCC1CC1 FAUQRRGKJKMEIW-UHFFFAOYSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-M 2-ethylhexanoate Chemical compound CCCCC(CC)C([O-])=O OBETXYAYXDNJHR-UHFFFAOYSA-M 0.000 description 1
- GNFVFPBRMLIKIM-UHFFFAOYSA-N 2-fluoroacetonitrile Chemical compound FCC#N GNFVFPBRMLIKIM-UHFFFAOYSA-N 0.000 description 1
- YXDXXGXWFJCXEB-UHFFFAOYSA-N 2-furonitrile Chemical compound N#CC1=CC=CO1 YXDXXGXWFJCXEB-UHFFFAOYSA-N 0.000 description 1
- UUMYLEFEBFEESC-UHFFFAOYSA-N 2-methyl-4-(trifluoromethyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylic acid Chemical compound C1N(C(O)=O)CCC2=C1N=C(C)N=C2C(F)(F)F UUMYLEFEBFEESC-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- MLSQPLWVDYIYGE-UHFFFAOYSA-N 2-phenyl-4-(trifluoromethyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylic acid Chemical compound C1N(C(=O)O)CCC(C(=N2)C(F)(F)F)=C1N=C2C1=CC=CC=C1 MLSQPLWVDYIYGE-UHFFFAOYSA-N 0.000 description 1
- YLWHWGDVASMPCA-UHFFFAOYSA-N 2-propan-2-yl-4-(trifluoromethyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylic acid Chemical compound C1N(C(O)=O)CCC2=C1N=C(C(C)C)N=C2C(F)(F)F YLWHWGDVASMPCA-UHFFFAOYSA-N 0.000 description 1
- SQJGNSAIKZMRLQ-UHFFFAOYSA-N 2-pyridin-3-yl-4-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine;hydrochloride Chemical compound Cl.N=1C=2CNCCC=2C(C(F)(F)F)=NC=1C1=CC=CN=C1 SQJGNSAIKZMRLQ-UHFFFAOYSA-N 0.000 description 1
- LBRWLAPXEJPBRT-UHFFFAOYSA-N 2-tert-butyl-4-(trifluoromethyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylic acid Chemical compound C1N(C(O)=O)CCC2=C1N=C(C(C)(C)C)N=C2C(F)(F)F LBRWLAPXEJPBRT-UHFFFAOYSA-N 0.000 description 1
- FSTQCUMTCUMTIW-UHFFFAOYSA-N 2-thiophen-2-yl-4-(trifluoromethyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylic acid Chemical compound C1N(C(=O)O)CCC(C(=N2)C(F)(F)F)=C1N=C2C1=CC=CS1 FSTQCUMTCUMTIW-UHFFFAOYSA-N 0.000 description 1
- YNFSLLCWLACNPY-UHFFFAOYSA-N 2-thiophen-3-yl-4-(trifluoromethyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylic acid Chemical compound C1N(C(=O)O)CCC(C(=N2)C(F)(F)F)=C1N=C2C=1C=CSC=1 YNFSLLCWLACNPY-UHFFFAOYSA-N 0.000 description 1
- FNIWQASUVMMYGX-UHFFFAOYSA-N 3,4-difluorobenzenecarboximidamide Chemical compound NC(=N)C1=CC=C(F)C(F)=C1 FNIWQASUVMMYGX-UHFFFAOYSA-N 0.000 description 1
- BTBFCBQZFMQBNT-UHFFFAOYSA-N 3,4-difluorobenzonitrile Chemical compound FC1=CC=C(C#N)C=C1F BTBFCBQZFMQBNT-UHFFFAOYSA-N 0.000 description 1
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
- NTHYHAZEHRVFLV-UHFFFAOYSA-N 3-(2-methoxy-2-oxoethyl)sulfanylbutanoic acid Chemical compound COC(=O)CSC(C)CC(O)=O NTHYHAZEHRVFLV-UHFFFAOYSA-N 0.000 description 1
- MFPMUSNWKAXBCK-UHFFFAOYSA-N 3-(trifluoromethyl)-4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c]pyridine;hydrochloride Chemical compound Cl.C1NCCC2=C1NN=C2C(F)(F)F MFPMUSNWKAXBCK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- BFJMHTOBRRZELQ-UHFFFAOYSA-N 3-iodo-2h-pyrazolo[3,4-c]pyridine Chemical compound N1=CC=C2C(I)=NNC2=C1 BFJMHTOBRRZELQ-UHFFFAOYSA-N 0.000 description 1
- OOWFYDWAMOKVSF-UHFFFAOYSA-N 3-methoxypropanenitrile Chemical compound COCCC#N OOWFYDWAMOKVSF-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FMHRQOZMPIETBA-UHFFFAOYSA-N 4-(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine Chemical compound C1NCCC2=C1N=CN=C2C(F)(F)F FMHRQOZMPIETBA-UHFFFAOYSA-N 0.000 description 1
- OXZYBOLWRXENKT-UHFFFAOYSA-N 4-(trifluoromethyl)benzoyl chloride Chemical compound FC(F)(F)C1=CC=C(C(Cl)=O)C=C1 OXZYBOLWRXENKT-UHFFFAOYSA-N 0.000 description 1
- DTQHGYWIQFGPSU-MRVPVSSYSA-N 4-[(5r)-5-methyl-2-oxopiperidin-1-yl]butanoic acid Chemical compound C[C@@H]1CCC(=O)N(CCCC(O)=O)C1 DTQHGYWIQFGPSU-MRVPVSSYSA-N 0.000 description 1
- AEKVBBNGWBBYLL-UHFFFAOYSA-N 4-fluorobenzonitrile Chemical compound FC1=CC=C(C#N)C=C1 AEKVBBNGWBBYLL-UHFFFAOYSA-N 0.000 description 1
- CZKLEJHVLCMVQR-UHFFFAOYSA-N 4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1 CZKLEJHVLCMVQR-UHFFFAOYSA-N 0.000 description 1
- UZOFELREXGAFOI-UHFFFAOYSA-N 4-methylpiperidine Chemical compound CC1CCNCC1 UZOFELREXGAFOI-UHFFFAOYSA-N 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 1
- MOSYBPLTLNVHPZ-UHFFFAOYSA-N C1N(C(=O)O)CCC(C(=N2)C(F)(F)F)=C1N=C2C1=CC=C(F)C=C1 Chemical compound C1N(C(=O)O)CCC(C(=N2)C(F)(F)F)=C1N=C2C1=CC=C(F)C=C1 MOSYBPLTLNVHPZ-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- LINDOXZENKYESA-UHFFFAOYSA-N TMG Natural products CNC(N)=NC LINDOXZENKYESA-UHFFFAOYSA-N 0.000 description 1
- STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- OYKRTHZDBLBNKK-HOCLYGCPSA-N [(2S)-1-[(2S)-2-methyl-5-oxomorpholin-4-yl]-4-oxo-4-[2-phenyl-4-(trifluoromethyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]butan-2-yl]carbamic acid Chemical compound O=C1CO[C@@H](C)CN1C[C@@H](NC(O)=O)CC(=O)N1CC(N=C(N=C2C(F)(F)F)C=3C=CC=CC=3)=C2CC1 OYKRTHZDBLBNKK-HOCLYGCPSA-N 0.000 description 1
- CZHAGFIOEUSAMK-SCSAIBSYSA-N [(2r)-2-methyl-3-oxopropyl]carbamic acid Chemical compound O=C[C@H](C)CNC(O)=O CZHAGFIOEUSAMK-SCSAIBSYSA-N 0.000 description 1
- CZHAGFIOEUSAMK-BYPYZUCNSA-N [(2s)-2-methyl-3-oxopropyl]carbamic acid Chemical compound O=C[C@@H](C)CNC(O)=O CZHAGFIOEUSAMK-BYPYZUCNSA-N 0.000 description 1
- FIPLAFRCDDWERW-UHFFFAOYSA-N [1,3]thiazolo[4,5-c]pyridine Chemical compound N1=CC=C2SC=NC2=C1 FIPLAFRCDDWERW-UHFFFAOYSA-N 0.000 description 1
- QQIRAVWVGBTHMJ-UHFFFAOYSA-N [dimethyl-(trimethylsilylamino)silyl]methane;lithium Chemical compound [Li].C[Si](C)(C)N[Si](C)(C)C QQIRAVWVGBTHMJ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- NMVVJCLUYUWBSZ-UHFFFAOYSA-N aminomethylideneazanium;chloride Chemical compound Cl.NC=N NMVVJCLUYUWBSZ-UHFFFAOYSA-N 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- LZCZIHQBSCVGRD-UHFFFAOYSA-N benzenecarboximidamide;hydron;chloride Chemical compound [Cl-].NC(=[NH2+])C1=CC=CC=C1 LZCZIHQBSCVGRD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- GFBLFDSCAKHHGX-UHFFFAOYSA-N cyclobutanecarbonitrile Chemical compound N#CC1CCC1 GFBLFDSCAKHHGX-UHFFFAOYSA-N 0.000 description 1
- IWYMAMAHNKEYNI-UHFFFAOYSA-N cyclopentanecarboximidamide;hydrochloride Chemical compound Cl.NC(=N)C1CCCC1 IWYMAMAHNKEYNI-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- WCQOBLXWLRDEQA-UHFFFAOYSA-N ethanimidamide;hydrochloride Chemical compound Cl.CC(N)=N WCQOBLXWLRDEQA-UHFFFAOYSA-N 0.000 description 1
- ZKRJCMKLCDWROR-ONEGZZNKSA-N ethyl (e)-4,4,4-trifluorobut-2-enoate Chemical compound CCOC(=O)\C=C\C(F)(F)F ZKRJCMKLCDWROR-ONEGZZNKSA-N 0.000 description 1
- OGTZLTXCAAKHNT-UHFFFAOYSA-N ethyl 2-(1-aminopropan-2-yloxy)acetate;hydrochloride Chemical compound Cl.CCOC(=O)COC(C)CN OGTZLTXCAAKHNT-UHFFFAOYSA-N 0.000 description 1
- OGTZLTXCAAKHNT-FYZOBXCZSA-N ethyl 2-[(2r)-1-aminopropan-2-yl]oxyacetate;hydrochloride Chemical compound Cl.CCOC(=O)CO[C@H](C)CN OGTZLTXCAAKHNT-FYZOBXCZSA-N 0.000 description 1
- KHVUTUHWRKYNPL-VIFPVBQESA-N ethyl 2-[(2s)-1-[(2-methylpropan-2-yl)oxycarbonylamino]propan-2-yl]oxyacetate Chemical compound CCOC(=O)CO[C@@H](C)CNC(=O)OC(C)(C)C KHVUTUHWRKYNPL-VIFPVBQESA-N 0.000 description 1
- OGTZLTXCAAKHNT-RGMNGODLSA-N ethyl 2-[(2s)-1-aminopropan-2-yl]oxyacetate;hydrochloride Chemical compound Cl.CCOC(=O)CO[C@@H](C)CN OGTZLTXCAAKHNT-RGMNGODLSA-N 0.000 description 1
- IPUCSNDZZBBYDJ-UHFFFAOYSA-N ethyl 3-(aminomethyl)-4,4,4-trifluorobutanoate Chemical compound CCOC(=O)CC(CN)C(F)(F)F IPUCSNDZZBBYDJ-UHFFFAOYSA-N 0.000 description 1
- ALVDYXPUTPYUQA-UHFFFAOYSA-N ethyl 4,4,4-trifluoro-3-(nitromethyl)butanoate Chemical compound CCOC(=O)CC(C(F)(F)F)C[N+]([O-])=O ALVDYXPUTPYUQA-UHFFFAOYSA-N 0.000 description 1
- DMVNCAACDMFLMD-UHFFFAOYSA-N ethyl 5-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(trifluoromethyl)pentanoate Chemical compound CCOC(=O)CC(C(F)(F)F)CCNC(=O)OC(C)(C)C DMVNCAACDMFLMD-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 150000002222 fluorine compounds Chemical group 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- ZQFYJHMUAWCEBH-UHFFFAOYSA-N furan-3-carbonitrile Chemical compound N#CC=1C=COC=1 ZQFYJHMUAWCEBH-UHFFFAOYSA-N 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- LRDFRRGEGBBSRN-UHFFFAOYSA-N isobutyronitrile Chemical compound CC(C)C#N LRDFRRGEGBBSRN-UHFFFAOYSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- BYRPTKZOXNFFDB-UHFFFAOYSA-N lithium;bis(trimethylsilyl)azanide;oxolane Chemical compound [Li+].C1CCOC1.C[Si](C)(C)[N-][Si](C)(C)C BYRPTKZOXNFFDB-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- JZHNQALXNGWKCG-SSDOTTSWSA-N methyl (2r)-2-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound COC(=O)[C@H](C)CNC(=O)OC(C)(C)C JZHNQALXNGWKCG-SSDOTTSWSA-N 0.000 description 1
- AWKLAGQCWMZXOZ-SCSAIBSYSA-N methyl (2r)-3-azido-2-methylpropanoate Chemical compound COC(=O)[C@H](C)CN=[N+]=[N-] AWKLAGQCWMZXOZ-SCSAIBSYSA-N 0.000 description 1
- JZHNQALXNGWKCG-ZETCQYMHSA-N methyl (2s)-2-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound COC(=O)[C@@H](C)CNC(=O)OC(C)(C)C JZHNQALXNGWKCG-ZETCQYMHSA-N 0.000 description 1
- AWKLAGQCWMZXOZ-BYPYZUCNSA-N methyl (2s)-3-azido-2-methylpropanoate Chemical compound COC(=O)[C@@H](C)CN=[N+]=[N-] AWKLAGQCWMZXOZ-BYPYZUCNSA-N 0.000 description 1
- ATCCIZURPPEVIZ-BYPYZUCNSA-N methyl (2s)-3-hydroxy-2-methylpropanoate Chemical compound COC(=O)[C@@H](C)CO ATCCIZURPPEVIZ-BYPYZUCNSA-N 0.000 description 1
- LHOFUYMABMHQEY-SECBINFHSA-N methyl (4r)-4-methyl-5-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate Chemical compound COC(=O)CC[C@@H](C)CNC(=O)OC(C)(C)C LHOFUYMABMHQEY-SECBINFHSA-N 0.000 description 1
- UIJPNDQJMMBMCW-VIFPVBQESA-N methyl (4s)-4-methyl-5-[(2-methylpropan-2-yl)oxycarbonylamino]pent-2-enoate Chemical compound COC(=O)C=C[C@H](C)CNC(=O)OC(C)(C)C UIJPNDQJMMBMCW-VIFPVBQESA-N 0.000 description 1
- MCVVUJPXSBQTRZ-ONEGZZNKSA-N methyl (e)-but-2-enoate Chemical compound COC(=O)\C=C\C MCVVUJPXSBQTRZ-ONEGZZNKSA-N 0.000 description 1
- UJZYDBAYCNIWFM-UHFFFAOYSA-N methyl 2-(1-aminopropan-2-ylsulfanyl)acetate Chemical compound COC(=O)CSC(C)CN UJZYDBAYCNIWFM-UHFFFAOYSA-N 0.000 description 1
- VUDYMLJTMNBXCU-UHFFFAOYSA-N methyl 2-[1-[(4-methoxyphenyl)methylamino]propan-2-ylsulfanyl]acetate Chemical compound COC(=O)CSC(C)CNCC1=CC=C(OC)C=C1 VUDYMLJTMNBXCU-UHFFFAOYSA-N 0.000 description 1
- MKIJJIMOAABWGF-UHFFFAOYSA-N methyl 2-sulfanylacetate Chemical compound COC(=O)CS MKIJJIMOAABWGF-UHFFFAOYSA-N 0.000 description 1
- KKRBFHDEOGWXNV-UHFFFAOYSA-N methyl 4-(aminomethyl)-5,5,5-trifluoropentanoate Chemical compound COC(=O)CCC(CN)C(F)(F)F KKRBFHDEOGWXNV-UHFFFAOYSA-N 0.000 description 1
- IBCSLFLNIFFAEP-UHFFFAOYSA-N methyl 4-amino-2-fluorobutanoate Chemical compound COC(=O)C(F)CCN IBCSLFLNIFFAEP-UHFFFAOYSA-N 0.000 description 1
- GDFIJRYYTPEXLE-UHFFFAOYSA-N methyl 4-amino-2-fluorobutanoate;hydrochloride Chemical compound Cl.COC(=O)C(F)CCN GDFIJRYYTPEXLE-UHFFFAOYSA-N 0.000 description 1
- RLQGFMIEMSPTCP-UHFFFAOYSA-N methyl 4-amino-2-methylbutanoate Chemical compound COC(=O)C(C)CCN RLQGFMIEMSPTCP-UHFFFAOYSA-N 0.000 description 1
- KVQGGLZHHFGHPU-UHFFFAOYSA-N methyl 4-aminobutanoate Chemical compound COC(=O)CCCN KVQGGLZHHFGHPU-UHFFFAOYSA-N 0.000 description 1
- YJXWIXXPQNNUTN-UHFFFAOYSA-N methyl 5,5,5-trifluoro-4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]pentanoate Chemical compound COC(=O)CCC(C(F)(F)F)CNC(=O)OC(C)(C)C YJXWIXXPQNNUTN-UHFFFAOYSA-N 0.000 description 1
- ACTYAFPVKSLFAQ-UHFFFAOYSA-N methyl 5-amino-2-fluoropentanoate Chemical compound COC(=O)C(F)CCCN ACTYAFPVKSLFAQ-UHFFFAOYSA-N 0.000 description 1
- NMBPMYCGGMADQX-UHFFFAOYSA-N methyl 5-amino-3-methylpentanoate Chemical compound COC(=O)CC(C)CCN NMBPMYCGGMADQX-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- RLKHFSNWQCZBDC-UHFFFAOYSA-N n-(benzenesulfonyl)-n-fluorobenzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)N(F)S(=O)(=O)C1=CC=CC=C1 RLKHFSNWQCZBDC-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- RYGUCYSSMOFTSH-UHFFFAOYSA-N oxane-4-carbonyl chloride Chemical compound ClC(=O)C1CCOCC1 RYGUCYSSMOFTSH-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- FVGUUJNEJJPLCS-UHFFFAOYSA-N pyridine-3-carboximidamide Chemical compound NC(=N)C1=CC=CN=C1 FVGUUJNEJJPLCS-UHFFFAOYSA-N 0.000 description 1
- GPHQHTOMRSGBNZ-UHFFFAOYSA-N pyridine-4-carbonitrile Chemical compound N#CC1=CC=NC=C1 GPHQHTOMRSGBNZ-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- QHSPZGZEUDEIQM-AATRIKPKSA-N tert-butyl (e)-but-2-enoate Chemical compound C\C=C\C(=O)OC(C)(C)C QHSPZGZEUDEIQM-AATRIKPKSA-N 0.000 description 1
- UNWFBXRLJJAFDG-UHFFFAOYSA-N tert-butyl 2-(2-methoxyethyl)-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC2=C1N=C(CCOC)N=C2C(F)(F)F UNWFBXRLJJAFDG-UHFFFAOYSA-N 0.000 description 1
- AJPHELRUJFXFEX-UHFFFAOYSA-N tert-butyl 2-(3-fluorophenyl)-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(C(=N2)C(F)(F)F)=C1N=C2C1=CC=CC(F)=C1 AJPHELRUJFXFEX-UHFFFAOYSA-N 0.000 description 1
- AYHUVQNYWOSJAS-UHFFFAOYSA-N tert-butyl 2-ethyl-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC2=C1N=C(CC)N=C2C(F)(F)F AYHUVQNYWOSJAS-UHFFFAOYSA-N 0.000 description 1
- ZWKLZLSLKBRSNV-UHFFFAOYSA-N tert-butyl 2-propyl-4-(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC2=C1N=C(CCC)N=C2C(F)(F)F ZWKLZLSLKBRSNV-UHFFFAOYSA-N 0.000 description 1
- NCEPJICBDNHZFK-UHFFFAOYSA-N tert-butyl 3-(2-methoxy-2-oxoethyl)sulfanylbutanoate Chemical compound COC(=O)CSC(C)CC(=O)OC(C)(C)C NCEPJICBDNHZFK-UHFFFAOYSA-N 0.000 description 1
- MMPWHAJQEZIIEH-UHFFFAOYSA-N tert-butyl 7-oxa-4-azabicyclo[4.1.0]heptane-4-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC2OC21 MMPWHAJQEZIIEH-UHFFFAOYSA-N 0.000 description 1
- MFPWEWYKQYMWRO-UHFFFAOYSA-N tert-butyl carboxy carbonate Chemical compound CC(C)(C)OC(=O)OC(O)=O MFPWEWYKQYMWRO-UHFFFAOYSA-N 0.000 description 1
- YNJCFDAODGKHAV-LURJTMIESA-N tert-butyl n-[(2s)-2-hydroxypropyl]carbamate Chemical compound C[C@H](O)CNC(=O)OC(C)(C)C YNJCFDAODGKHAV-LURJTMIESA-N 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- SMJRBWINMFUUDS-UHFFFAOYSA-M thien-2-ylacetate Chemical compound [O-]C(=O)CC1=CC=CS1 SMJRBWINMFUUDS-UHFFFAOYSA-M 0.000 description 1
- CUPOOAWTRIURFT-UHFFFAOYSA-N thiophene-2-carbonitrile Chemical compound N#CC1=CC=CS1 CUPOOAWTRIURFT-UHFFFAOYSA-N 0.000 description 1
- QSELGEUCFNFITD-UHFFFAOYSA-N thiophene-2-carboximidamide Chemical compound NC(=N)C1=CC=CS1 QSELGEUCFNFITD-UHFFFAOYSA-N 0.000 description 1
- GSXCEVHRIVLFJV-UHFFFAOYSA-N thiophene-3-carbonitrile Chemical compound N#CC=1C=CSC=1 GSXCEVHRIVLFJV-UHFFFAOYSA-N 0.000 description 1
- YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Definitions
- the present invention relates to compounds of novel structure, having good inhibition activity versus Dipeptidyl Peptidase-IV (DPP-IV), methods of preparing the same and pharmaceutical compositions containing the same as an active agent.
- DPP-IV Dipeptidyl Peptidase-IV
- Diabetes mellitus has serious effects on people's health and accompanies various complications.
- type I diabetes mellitus characterized by little or no insulin secretory capacity due to the destruction of pancreatic cells
- type II diabetes mellitus characterized by insulin deficiency and insulin resistance due to other causes.
- the prevalence of type II diabetes mellitus is 90% or more of total patients with diabetes mellitus.
- Representative examples of complications accompanying diabetes include hyperlipidemia, hypertension, retinopathy and renal insufficiency (Paul Zimmer, et al., Nature, 2001, 414, 782).
- Sulfonylureas (stimulating insulin secretion in pancreatic cells), biguanides (inhibiting glucose production in the liver), ⁇ -glucosidase inhibitors (inhibiting glucose absorption in the intestines), etc. have been used as agents to treat diabetes.
- PP AR ⁇ peroxisome pro- liferator-activated receptor gamma
- Thiazolidinediones increasing insulin sensitivity
- these drugs have side effects such as hypoglycemia, weight gain and the like (David E. Moller, Nature, 2001, 414, 821). Accordingly, there is a strong need to develope diabetes therapeutic agents with decreased side effects, in particular without inducing hypoglycemia and weight gain.
- DPP-IV dipeptidyl peptidase-IV
- GLP-I glucagon-like protein 1
- DPP-IV inhibitors are also being developed as a treatment for obesity because they lead to satiety in rats and slow down digestion of foods in the intestines, resulting in weight loss. Further, many investigators have also shown that DPP-IV inhibitors control blood glucose and lipid levels in animal experiments (Pospislik J. A., et al, Diabetes, (2002) 51, 943-950). In this regard, DPP-IV inhibitors can be considered as potentially useful agents for treatement of diabetes.
- R is an adamantyl group
- n is 0 to 3.
- U, V and W are nitrogen, oxygen, or substituted nitrogen or carbon.
- WO 03/004498 dicloses DPP-IV inhibitors represented by the below formula.
- Ar is unsubstituted or substituted phenyl group; R is hydrogen or alkyl
- WO 03/082817 dicloses DPP-IV inhibitors represented by the below formula.
- Ar is unsubstituted or substituted phenyl group; R , R and R are hydrogen or alkyl group; and Q is nitrogen or substituted carbon.
- DPP-IV inhibitors has the amide bond in their molecular structures likewise the present invention; however, the unsubstituted or substituted phenyl groups which is represented as Ar in the above formulas of these inhibitors are entirely different from the saturated or unsaturated, 5-membered or 6-membered heterocyclic substituents of the present invention. Moreover, DPP-IV inhibitors of the present invention having the lactam ring at the phenyl group position of the above inhibitors have not been disclosed in the prior art. Disclosure of Invention Technical Problem
- R is hydrogen, or substituted or unsubstituted C -C alkyl
- R is hydrogen, or substituted or unsubstituted alkyl, cycloalkyl, aryl or heteroaryl; and R' is hydrogen, CF ;
- R is hydrogen, halogen, or substituted or unsubstituted C -C alkyl, or
- R is hydrogen, halogen, or substituted or unsubstituted C -C alkyl
- R is halogen, or substituted or unsubstituted C -C alkyl;
- B is selected from the group consisting of substituents of Formulas 8 to 11 below:
- R , R , R and R are each independently hydrogen, halogen, or
- R , R and R are each independently hydrogen, halogen, or substituted or unsubstituted C -C alkyl; and Y is oxygen, sulfur or SO ; [45] (Q)
- R and R are each independently hydrogen, halogen, or substituted or
- R is substituted or unsubstituted C -C alkyl.
- C 1 -C 4 alkyl is substituted, as defined in the above formula, it is preferably the alkyl substituted with halogen, and more preferably the alkyl substituted with fluoride.
- R in Formula 5 is selected from the group consisting of the below substituents: [52] (D) hydrogen;
- R and R are each independently hydrogen, halogen, or substituted or unsubstituted C 1 -C 4 alkyl;
- C -C cycloalkyl and C -C alkyl are of a substituted form, they are preferably the cycloalkyl and alkyl substituted with halogen or hydroxy.
- the preferable examples of the heteroaryl as defined above include, but not limited to 2-furane, 3-furane, 2-thiophene, 3-thiophene, 2-pyridine, 3-pyridine, 4-pyridine,
- the compounds according to the present invention include isomers thereof, and a preferable isomer is the compound of Formula Ia below in which the carbon adjacent to NH is a chiral center: [61]
- the compound of the present invention may form an acid adduct with a pharmaceutically acceptable acid.
- the pharmaceutically acceptable salt includes inorganic salts, organic salts, amino acid salts, etc., and more specifically, salts with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid; salts with organic carboxylic acids such as acetic acid, citric acid, trifluoroacetic acid, formic acid, maleic acid, oxalic acid, succinic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, ascorbic acid, malic acid and the like; salts with methanesulfonic acid, p-toluenesulfonic acid and the like.
- the compound of the present invention or the pharmaceutically acceptable salts thereof can be present in a form of hydrate or solvate.
- the compounds of Formula 1 according to the present invention are compounds as defined below: [66] 3-[2S-amino-4-oxo-4-(3-trifluoromethyl-5,6-dihydro-8H-[l,2,4]triazolo[4,3-a]pyraz in-7-yl)-butyl]-oxazolidin-2-one; [67] 3-[2S-amino-4-oxo-4-(3-trifluoromethyl-5,6-dihydro-8H-[l,2,4]triazolo[4,3-a]pyraz in-7-yl)-butyl]-5-methyl-oxazolidin-2-one; [68] l-[2S-amino-4-oxo-4-(3-trifluoromethyl-5,6-dihydro-8H-[
- the compound of Formula 1 can be prepared by a process comprising a step of reacting the compound of Formula
- R is selected from the group consisting of the substituents of Formulas 13a to 13d: [188]
- A, B, Y, Z, R 7, R 8, R 9, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 and R 17 are the same as defined above; [194] R 22 , R 23 , R 24 and R 25 are each indep ⁇ endently J C 1 -C 3 alky J l;
- P is amine-protecting group
- G is nothing, or hydrochloric acid, sulfuric acid or trifluoroacetic acid.
- the above reaction can be conducted in the presence of an oraganic solvent such as dichloroethane or cyclic ether (e.g., tetrahydrofuran (THF)) at a temperature of -10 to
- reaction product can be isolated and purified from the reactants by means of conventional methods such as chromatography.
- reaction product can be isolated and purified from the reactants by means of conventional methods such as chromatography.
- [202] a is ClCO 2 Et, Et 3 N, THF; NaBH 4 , MeOH;
- b is TBSCl, imidazole, DMF;
- c is Pd/C, H (benzyl ester) or LiOH-H O, MeOH-H O (methyl or ethyl ester);
- d is EDC, HOBT, AH;
- e is TBAF, THF
- f is Swern [O] or Dess Martin [O] ;
- P is benzyl, methyl or ethyl.
- the carboxylic acid of Formula 14 above is converted into an ester anhydride which is then reducted using NaBH 4 in a presence of methanol solvent to product a primary alcohol.
- the resulting primary alcohol is protected with t-butyl dimethyl silyl group, then in the case of a benzyl ester form, a hydrolysis reaction is carried out using platinum complex and hydrogen, and in the case of methyl or ethyl form, a hydrolysis reaction is carried out using lithium hydroxide, thereby obtaining a carboxylic acid.
- a desired amine group can be converted into by a coupling reaction using EDC and HOBT, then TBS group is removed, followed by oxidation with Swern or Dess-Martin to obtain an aldehyde of Formula 12.
- the amine- protecting group is Boc, it can be removed using TFA or HCl, and where the amine- protecting group is Cbz, it can be removed using H /Pd/C or TMSI, and where the amine-protecting group is Fmoc, it can be removed using Et NH.
- An amine 'A' in Formula 12 can be prepared by methods set forth in WO
- the compound of Formula 12 can be synthesized from the compound of Formula 14 with reference to a known process (e.g., J. Med. Chem. 1999, 42(18), 3557-3571; WO 04/069162 etc.).
- the compound of Formula 1 can be prepared by a process comprising a step of reacting the compound of Formula 13 above with the compound of Formula 15 below, a step of removing an acid- protecting group P : and a step of reacting the resulting product with a compound of Formula AH (wherein A is the same as in Formula 1), followed by removing an amine- protecting group:
- P is benzyl or t-buthyl.
- [222] a) is Na(OAc) 3 BH, R ⁇ NH ⁇ , and ClCH 2 CH 2 Cl;
- [224] c) is EDC, HOBT, AH;
- P is an amine-protecting group such as Boc, Cbz or Fmoc
- P is benzyl or t-butyl
- G is nothing, or hydrochloric acid, sulfuric acid or trifluoroacetic acid.
- a method for preparation of a compound of Formula 16 is known (e.g., J. Med.
- Reaction a) is conducted in the presence of an organic solvent such as dichloroethane or cyclic ether (e.g., tetrahydrofuran (THF)) at a temperature of -10 to 40°C by reacting a compound of Formula 15 with preferably 0.7 to 1.5 equivalent of a primary amine (a compound of Formula 13).
- an organic solvent such as dichloroethane or cyclic ether (e.g., tetrahydrofuran (THF)
- THF tetrahydrofuran
- a cyclization reaction is further procedured at the same condition as above to synthesize a compound of Formula 16, and the compound of Formula 16 is converted a carboxylic acid of Formula 17 via Reaction b).
- a compound of Formula 20 can be prepared by making an enolate from a compound of Formula 19 using LHMDS and then adding tr ifluo- roacetate thereto (reference: J. Fluorine Chem. 2003, 123(2), 267-272).
- tr ifluo- roacetate thereto
- There are various methods of preparing a compound 21 having a pyrimidine ring from a compound of Formula 20, and among them, a method of using BF OEt as a catalyst (Synthesis 2000, 12, 1738-1748) and a method of using pyridine as a solvent (Tetrahedron 1983, 39(19), 3197-3199) are preferable to obtain the good yield.
- a desired compound of Formula 22 can be obtained.
- the compound of Formula 1 can be prepared by a process comprising a step of reacting the compound of Formula 15 above with the compound of Formula 23 below:
- G is nothing or acid, preferably hydrochloric acid, sulfuric acid or trifluoroacetic acid;
- R is hydrogen, substituted or unsubstituted C -C alkyl.
- a compound of Formula 1 can be isolated and purified from the reaction product by means of conventional methods such as recrystallization, ion electrophoresis, silica gel column chromatography, ion exchange resin chromatography and the like.
- the present invention provides a pharmaceutical composition for inhibiting
- DPP-IV comprising the compound of Formula 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- the compound of Formula 1 can be administered in various pharmaceutical dosage forms in accordance with intended use.
- an active agent more specifically a compound of Formula 1 may be mixed with one or more pharmaceutically acceptable carriers which can be selected depending on the dosage form to be prepared.
- the pharmaceutical composition according to the present invention can be formulated into dosage forms suitable for injection or oral administration.
- the compound of Formula 1 may be formulated in a conventional manner using known pharmaceutically acceptable carriers and excipients and presented in unit dosage form or in multidose containers.
- the formulations may take such forms as solutions, suspensions or emulsions in oily or aqueous vehicles, and may contain conventional dispersing, suspending or stabilizing agents.
- the active ingredient may be in powder form for reconstitution with sterile pyrogen-free water, before use.
- the compound of Formula 1 may also be formulated into suppositories containing conventional suppository bases such as cocoa butter or other glycerides.
- Solid dosage forms for oral administration include capsule, tablet, pill, powder and granule. Preferable dosage forms are capsule and tablet. It is preferable that tablets and pills be coated.
- the solid dosage forms for oral administration may be obtained by mixing the compound of Formula 1 as an active agent with inactive diluents such as sucrose, lactose, starch and the like and carriers such as lubricant, for example magnesium stearate, including disintegrator, binder and the like.
- inactive diluents such as sucrose, lactose, starch and the like
- carriers such as lubricant, for example magnesium stearate, including disintegrator, binder and the like.
- the compound of Formula 1 and compositions comprising the same according to the present invention may be administrated in combination with other pharmaceutical agents, for example, other diabetes treating agents.
- the dosage amount of the compound of Formula 1 as an active agent can be preferably contained in an amount of about 0.1 ⁇ 1,500 mg unit dosage.
- the dosage amount of the compound of Formula 1 will be dependent on the subject's weight and age, the nature and severity of the affliction and the judgment of the prescribing physician.
- the dosage amount required will be about in the range of 1 to 500 mg a day depending on the frequency and strength of the dosage.
- a total dosage amount of about 5 ⁇ 300 mg a day will be sufficient. In some patients, the dosage amount in a day will be higher than that.
- the present invention provides the use of the compound of Formula 1 as defined in claim 1 for manufacture of a medicament for the treatment or prevention of diseases involving inappropriate activity of DPP-IV.
- Representative examples of the diseases caused by inappropriate levels of DPP-IV include, but are in no way limited to, diabetes mellitus, obesity and the like as described above.
- diabetes mellitus the present invention is preferred to treat and prevent type II diabetes mellitus.
- PREPARATION 1 Synthesis of 3-aminomethyl-4.4.4-trifluoro-butanoic acid ethyl ester hydrochloric acid salt
- PREPARATION 2 Synthesis of 4-amino-3-methyl-butyric acid methyl ester hy- drochloric acid salt
- PREPARATION 3 Synthesis of 4-amino-2-fluoro-butyric acid methyl ester hy- drochloric acid salt [312] (1) Synthesis of 2-oxo-pyrolidin-l-carboxylic acid t-butyl ester
- PREPARATION 4 Synthesis of 5-amino-2-fluoro-pentanoic acid methyl ester hy- drochloric acid salt
- PREPARATION 7 Synthesis of fRV5-amino-4-methyl-pentanoic acid methyl ester hydrochloric acid salt
- PREPARATION 8 Synthesis of 5-amino-3-methyl-pentanoic acid methyl ester hy- drochloric acid salt
- PREPARATION 12 Synthesis of 5-amino-4.4-difluoro-pentanoic acid methyl ester hydrochloric acid salt
- PREPARATION 13 Synthesis of 3S-t-butoxycarbonylamino-4-hvdroxy-butyric acid benzyl ester
- reaction solution was diluted with excess ethyl acetate, and washed once with aqueous 1 N aqueous HCl and aqueous NaCl, respectively, then dried over anhydrous magnesium sulfate and filtered off.
- the filtrated solution was distilled off under reduced pressure, then the residue was purified by column chromatography (4:1 hexane: ethyl acetate) to give 4.44 g of the title compound in a yield of 72%
- PREPARATION 14 Synthesis of 3S-t-butoxycarbonylamino-4-oxo-butyric acid benzyl ester
- 3S-t-butoxycarbonylamino-4-(2-hydroxy-ethylamino)-butyric acid benzyl ester obtained in PREPARATION 15 was dissolved in dichloromethane and then cooled to 0°C, then 2801 (1.6 mmol) of N,N-diisopropylethylamine and 49 mg (0.4 mmol) of dimethylaminopyridine were added thereto, followed by addition of 0.4 g (0.6 mmol) of phosgene (20% toluene) followed by stirring for 2 hours and 40 minutes.
- EXAMPLE 7 Synthesis of l-r2S-amino-4-oxo-4-r3-trifluoromethyl-5.6-dihydro-8H-[1.2.4]triazolo[4.3-a]pyrazin- 7-yiybutyli- 3-fluoro-piperidin-2-one
- EXAMPLE 8 Synthesis of l-[2S-amino-4-oxo-4-(3-trifluoromethyl-5.6-dihydro-8H-[1.2.41triazolo[4.3-a1pyrazin- 7-yl)-butyl1-3-methyl-pyrolidin-2-one
- PREPARATION 41 Synthesis of 3S-t-butoxycarbonylamino-4-oxo-butrvic acid t- butyl ester
- reaction solution was diluted with dichloromethane, and an organic layer was washed once with aqueous IN aqueous hydrochloric acid and aqueous NaCl, respectively, then dried over anhydrous magnesium sulfate, followed by filtering and concentration under reduced pressure.
- the resulting compound was isolated and then the residue was purified by column chromatography to give 110 mg of the title compound in a yield of 61%.
- EDC were dropwise added in sequence at room temperature to a solution in which 20 mg (0.067 mmol) of 3S-t-butoxycarbonylamino-4-(2-oxo-piperidin-l-yl)-butryic acid obtained in PREPARATION 42 was dissolved in 10 mL of dimethylformamid. After srirring for 10 minutes, to the reaction solution, was dropwise added a solution in which 14 mg (0.073 mmol) of 3-trifluoromethyl-4,5,6,7-tetrahydro-isooxazol[3,4,c] pyridine obtained in PREPARATION 44 was dissolved in 3 mL of dimethyl- formamide.
- PREPARATION 48 Synthesis of 4-trifluoromethyl-5.8-dihvdro-6H-pyridor3.4-dl pyrimidin-7-carboxylic acid t-butylester
- PREPARATION 53 Synthesis of fSW2-amino-l-methyl-ethoxyVacetic acid ethyl ester hydrochloric acid salt
- PREPARATION 54 Synthesis of t-butyl GSy3-rft-butoxycarbonyDaminol -
- PREPARATION 56 Synthesis of t-butyl GSy3-rft-butoxycarbonvttaminol -
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI200331873T SI1863812T1 (sl) | 2005-04-01 | 2006-03-30 | Spojine za inhibicijo dipeptidil peptidaze IV postopek priprave le te in le to kot učinkovino vsebujoč farmacevtski sestavek |
PL06732744T PL1863812T3 (pl) | 2005-04-01 | 2006-03-30 | Związki hamujące dipeptydylo-peptydazę IV, sposoby ich wytwarzania oraz kompozycje farmaceutyczne zawierające je jako składnik aktywny |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20050027756 | 2005-04-01 | ||
KR20050053761 | 2005-06-22 | ||
KR20050085980 | 2005-09-15 | ||
KR20050122361 | 2005-12-13 | ||
PCT/KR2006/001169 WO2006104356A1 (en) | 2005-04-01 | 2006-03-30 | Dipeptidyl peptidase-iv inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1863812A1 EP1863812A1 (de) | 2007-12-12 |
EP1863812A4 true EP1863812A4 (de) | 2009-06-24 |
EP1863812B1 EP1863812B1 (de) | 2010-07-14 |
Family
ID=37053586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06732744A Active EP1863812B1 (de) | 2005-04-01 | 2006-03-30 | Dipeptidylpeptidase-iv-inhibierende verbindungen, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese als wirkstoffe enthalten |
Country Status (28)
Country | Link |
---|---|
US (1) | US7879848B2 (de) |
EP (1) | EP1863812B1 (de) |
JP (1) | JP4977685B2 (de) |
KR (3) | KR100776623B1 (de) |
CN (1) | CN101151265B (de) |
AR (1) | AR053195A1 (de) |
AT (1) | ATE473976T1 (de) |
AU (1) | AU2006229520B2 (de) |
BR (1) | BRPI0609424B8 (de) |
CA (1) | CA2602248C (de) |
DE (1) | DE602006015443D1 (de) |
DK (1) | DK1863812T3 (de) |
EA (1) | EA012591B1 (de) |
ES (1) | ES2349178T3 (de) |
IL (1) | IL185479A (de) |
MA (1) | MA29586B1 (de) |
MX (1) | MX2007012175A (de) |
MY (1) | MY150102A (de) |
NZ (1) | NZ560789A (de) |
PE (1) | PE20061354A1 (de) |
PL (1) | PL1863812T3 (de) |
PT (1) | PT1863812E (de) |
SI (1) | SI1863812T1 (de) |
TW (1) | TWI357902B (de) |
UA (1) | UA89396C2 (de) |
UY (1) | UY29448A1 (de) |
WO (1) | WO2006104356A1 (de) |
ZA (1) | ZA200708304B (de) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007148185A2 (en) | 2006-06-21 | 2007-12-27 | Pfizer Products Inc. | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors |
JP2010500300A (ja) | 2006-08-08 | 2010-01-07 | サノフィ−アベンティス | アリールアミノアリール−アルキル−置換イミダゾリジン−2,4−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用 |
WO2008120813A1 (ja) | 2007-04-03 | 2008-10-09 | Mitsubishi Tanabe Pharma Corporation | ジペプチジルペプチダーゼ4阻害化合物と甘味料との併用 |
CN101357922B (zh) * | 2007-08-02 | 2011-05-18 | 山东轩竹医药科技有限公司 | 新的dpp-iv抑制剂 |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
BRPI0820103A2 (pt) * | 2007-12-05 | 2015-05-05 | Astrazeneca Ab | Composto, formulação farmacêutica, uso de um composto, métodos para tratar ou prevenir condições ou doenças e para a inibição da angiogênese, e, processo para preparação de um composto |
CA2710109C (en) * | 2007-12-21 | 2016-07-19 | Lg Life Sciences Ltd. | Dipeptidyl peptidase-iv inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent |
CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
CN101486689B (zh) * | 2008-01-18 | 2011-08-10 | 山东轩竹医药科技有限公司 | 具有磺酰胺基甲酰胺哌嗪结构的dpp-iv抑制剂 |
US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
JO2870B1 (en) * | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
CA2754712A1 (en) | 2009-03-13 | 2010-09-16 | Sun Chemical B.V. | Cyclic carbamate compounds useful in energy-curable compositions |
CN102482312A (zh) | 2009-08-26 | 2012-05-30 | 赛诺菲 | 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途 |
US8871760B2 (en) * | 2009-09-21 | 2014-10-28 | Roche Palo Alto Llc | [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
CN102260265B (zh) * | 2010-05-24 | 2015-09-02 | 上海阳帆医药科技有限公司 | 六氢吡咯[3,4-b]吡咯衍生物、其制备方法及其用途 |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
CA2810393C (en) * | 2010-09-03 | 2016-04-12 | Lg Life Sciences Ltd. | Method of preparing 3-amino-4-(2-oxo-piperidin-1-yl)-butyric acid derivative for synthesizing medicament |
TWI519533B (zh) * | 2010-11-01 | 2016-02-01 | Lg生命科學有限公司 | 1-{(2S)-2-胺基-4-[2,4-雙(三氟甲基)-5,8-二氫吡啶并[3,4-d]嘧啶-7(6H)-基]-4-側氧丁基}-5,5-二氟哌啶-2-酮酒石酸鹽之水合物 |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US20150297573A1 (en) | 2012-10-24 | 2015-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL |
CN105085528A (zh) * | 2014-05-15 | 2015-11-25 | 成都贝斯凯瑞生物科技有限公司 | 作为二肽基肽酶-iv抑制剂的氨基四氢吡喃衍生物 |
ES2805743T3 (es) | 2015-03-24 | 2021-02-15 | Inst Nat Sante Rech Med | Método y composición farmacéutica para uso en el tratamiento de la diabetes |
AU2017223706A1 (en) | 2016-02-23 | 2018-09-20 | Indiana University Research & Technology Corporation | Combination therapies for treatment of spinal muscular atrophy |
KR102068754B1 (ko) * | 2017-04-20 | 2020-01-21 | 주식회사 엘지화학 | 의약품 합성용 중간체 화합물의 제조 방법 |
RU2741389C1 (ru) * | 2017-11-16 | 2021-01-25 | ЭлДжи КЕМ, ЛТД. | Способ получения промежуточного соединения для синтеза лекарственного средства |
CN108191647B (zh) * | 2018-02-22 | 2020-09-29 | 江苏尚莱特医药化工材料有限公司 | 2,2-二氟二羧酸二烷基酯的合成方法 |
CN111537622B (zh) * | 2019-11-29 | 2021-11-26 | 杭州华东医药集团新药研究院有限公司 | 一种度格列汀及其盐的杂质的检测方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004058266A1 (en) * | 2002-12-20 | 2004-07-15 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2004069162A2 (en) * | 2003-01-31 | 2004-08-19 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
US6861440B2 (en) * | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
AU2002360732A1 (en) | 2001-12-26 | 2003-07-24 | Guilford Pharmaceuticals | Change inhibitors of dipeptidyl peptidase iv |
JP2005526811A (ja) * | 2002-03-25 | 2005-09-08 | メルク エンド カムパニー インコーポレーテッド | 糖尿病の治療または予防用β−アミノ複素環式ジペプチジルペプチダーゼ阻害剤 |
AU2003223755B2 (en) | 2002-04-29 | 2008-08-21 | Merck Sharp & Dohme Corp. | Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity |
WO2004007468A1 (en) | 2002-07-15 | 2004-01-22 | Merck & Co., Inc. | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
JP2004285325A (ja) * | 2002-12-17 | 2004-10-14 | Fuji Photo Film Co Ltd | パターン形成方法及び物質付着パターン材料 |
US7265128B2 (en) * | 2003-01-17 | 2007-09-04 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
EP1732885A1 (de) * | 2004-02-23 | 2006-12-20 | Trustees Of Tufts College | Lactame als konformationsgehinderte peptidomimetische inhibitoren |
US7291427B2 (en) * | 2004-03-19 | 2007-11-06 | Fujifilm Corporation | Surface graft material, conductive pattern material, and production method thereof |
DE102004020908A1 (de) * | 2004-04-28 | 2005-11-17 | Grünenthal GmbH | Substituierte 5,6,7,8,-Tetrahydro-pyrido[4,3-d]pyrimidin-2-yl- und 5,6,7,8,-Tetrahydro-chinazolin-2-yl-Verbindungen |
DE102005016170A1 (de) * | 2005-04-07 | 2006-10-12 | Grünenthal GmbH | 4,5,6,7- Tetrahydro-isoxazolo(4,5c)pyridin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
ZA200709961B (en) * | 2005-05-10 | 2009-07-29 | Vertex Pharma | Bicyclic derivatives as modulators of ion channels |
WO2007136990A2 (en) * | 2006-05-16 | 2007-11-29 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
EP2229395A1 (de) * | 2008-01-17 | 2010-09-22 | Grünenthal GmbH | Substituierte sulfonamid-derivate |
-
2006
- 2006-03-21 TW TW095109718A patent/TWI357902B/zh active
- 2006-03-29 AR ARP060101214A patent/AR053195A1/es active IP Right Grant
- 2006-03-30 US US11/910,370 patent/US7879848B2/en active Active
- 2006-03-30 SI SI200331873T patent/SI1863812T1/sl unknown
- 2006-03-30 DK DK06732744.5T patent/DK1863812T3/da active
- 2006-03-30 BR BRPI0609424A patent/BRPI0609424B8/pt active IP Right Grant
- 2006-03-30 ES ES06732744T patent/ES2349178T3/es active Active
- 2006-03-30 UY UY29448A patent/UY29448A1/es not_active Application Discontinuation
- 2006-03-30 UA UAA200710765A patent/UA89396C2/ru unknown
- 2006-03-30 PL PL06732744T patent/PL1863812T3/pl unknown
- 2006-03-30 CA CA2602248A patent/CA2602248C/en active Active
- 2006-03-30 EP EP06732744A patent/EP1863812B1/de active Active
- 2006-03-30 MX MX2007012175A patent/MX2007012175A/es active IP Right Grant
- 2006-03-30 AT AT06732744T patent/ATE473976T1/de active
- 2006-03-30 KR KR1020060029138A patent/KR100776623B1/ko active IP Right Grant
- 2006-03-30 PE PE2006000351A patent/PE20061354A1/es active IP Right Grant
- 2006-03-30 PT PT06732744T patent/PT1863812E/pt unknown
- 2006-03-30 CN CN200680009935XA patent/CN101151265B/zh active Active
- 2006-03-30 MY MYPI20061446A patent/MY150102A/en unknown
- 2006-03-30 JP JP2008503954A patent/JP4977685B2/ja active Active
- 2006-03-30 EA EA200701854A patent/EA012591B1/ru unknown
- 2006-03-30 WO PCT/KR2006/001169 patent/WO2006104356A1/en active Application Filing
- 2006-03-30 AU AU2006229520A patent/AU2006229520B2/en active Active
- 2006-03-30 NZ NZ560789A patent/NZ560789A/en unknown
- 2006-03-30 DE DE602006015443T patent/DE602006015443D1/de active Active
-
2007
- 2007-08-23 IL IL185479A patent/IL185479A/en active IP Right Grant
- 2007-08-28 KR KR1020070086444A patent/KR100830902B1/ko active IP Right Grant
- 2007-08-28 KR KR1020070086486A patent/KR100794184B1/ko active IP Right Grant
- 2007-09-28 ZA ZA200708304A patent/ZA200708304B/xx unknown
- 2007-10-30 MA MA30343A patent/MA29586B1/fr unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004058266A1 (en) * | 2002-12-20 | 2004-07-15 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2004069162A2 (en) * | 2003-01-31 | 2004-08-19 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1863812B1 (de) | Dipeptidylpeptidase-iv-inhibierende verbindungen, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese als wirkstoffe enthalten | |
JP6177456B2 (ja) | 二環式縮合ヘテロアリールまたはアリール化合物およびirak4阻害剤としてのそれらの使用 | |
CA2683695C (en) | 3-amido-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldehyde derivatives | |
EP2170906B1 (de) | Kondensierte thiazol-derivate als kinase-hemmer | |
CN103025724B (zh) | 哌啶衍生物 | |
CA3079557A1 (en) | Dihydropyrimidine compounds and uses thereof in medicine | |
AU2007332493A1 (en) | Imidazothiazole derivatives | |
JPWO2009151069A1 (ja) | 4,7−ジアザスピロ[2.5]オクタン環構造を有するイミダゾチアゾール誘導体 | |
WO2009001126A1 (en) | Substituted piperidine derivatives and their use as antibaterial agents | |
EP2121702A1 (de) | 2-chinolinon- und 2-chinoxalinonderivate und deren verwendung als antibakterielle mittel | |
CN113950477B (zh) | 颗粒体蛋白前体调节剂和其使用方法 | |
JP2009298713A (ja) | イミダゾチアゾール誘導体 | |
CN118201916A (zh) | 用于治疗细菌感染的哌嗪基磺酰基芳基化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20070927 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK YU |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20090528 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 413/06 20060101ALI20090520BHEP Ipc: A61K 31/4355 20060101ALI20090520BHEP Ipc: C07D 498/04 20060101ALI20090520BHEP Ipc: A61K 31/4375 20060101ALI20090520BHEP Ipc: A61K 31/4985 20060101ALI20090520BHEP Ipc: C07D 471/04 20060101AFI20061025BHEP Ipc: C07D 513/04 20060101ALI20090520BHEP Ipc: C07D 487/04 20060101ALI20090520BHEP Ipc: C07D 401/06 20060101ALI20090520BHEP Ipc: A61K 31/4365 20060101ALI20090520BHEP Ipc: A61P 3/00 20060101ALI20090520BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK YU |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20100729 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: RO Ref legal event code: EPE |
|
REF | Corresponds to: |
Ref document number: 602006015443 Country of ref document: DE Date of ref document: 20100826 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: BOHEST AG |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20100402221 Country of ref document: GR |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20100714 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Effective date: 20101215 |
|
REG | Reference to a national code |
Ref country code: SK Ref legal event code: T3 Ref document number: E 8029 Country of ref document: SK |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100714 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100714 |
|
REG | Reference to a national code |
Ref country code: PL Ref legal event code: T3 Ref country code: HU Ref legal event code: AG4A Ref document number: E009001 Country of ref document: HU |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100714 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100714 |
|
26N | No opposition filed |
Effective date: 20110415 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602006015443 Country of ref document: DE Effective date: 20110415 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PCAR Free format text: NEW ADDRESS: HOLBEINSTRASSE 36-38, 4051 BASEL (CH) |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602006015443 Country of ref document: DE Representative=s name: PATENTANWAELTE WEICKMANN & WEICKMANN, DE Ref country code: DE Ref legal event code: R082 Ref document number: 602006015443 Country of ref document: DE Representative=s name: WEICKMANN & WEICKMANN PATENTANWAELTE - RECHTSA, DE Ref country code: DE Ref legal event code: R082 Ref document number: 602006015443 Country of ref document: DE Representative=s name: WEICKMANN & WEICKMANN PATENT- UND RECHTSANWAEL, DE |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 12 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: RPOT |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602006015443 Country of ref document: DE Representative=s name: WEICKMANN & WEICKMANN PATENTANWAELTE - RECHTSA, DE Ref country code: DE Ref legal event code: R081 Ref document number: 602006015443 Country of ref document: DE Owner name: LG CHEM, LTD., KR Free format text: FORMER OWNER: LG LIFE SCIENCES LTD., SEOUL/SOUL, KR Ref country code: DE Ref legal event code: R082 Ref document number: 602006015443 Country of ref document: DE Representative=s name: WEICKMANN & WEICKMANN PATENT- UND RECHTSANWAEL, DE |
|
REG | Reference to a national code |
Ref country code: LU Ref legal event code: HC Owner name: LG LIFE SCIENCES LTD.; KR Free format text: FORMER OWNER: LG LIFE SCIENCES LTD. Effective date: 20170823 Ref country code: LU Ref legal event code: PD Owner name: LG CHEM, LTD.; KR Free format text: FORMER OWNER: LG LIFE SCIENCES LTD. Effective date: 20170823 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: NOVAGRAAF INTERNATIONAL SA, CH Ref country code: CH Ref legal event code: PFUS Owner name: LG CHEM, LTD., KR Free format text: FORMER OWNER: LG LIFE SCIENCES LTD., KR Ref country code: CH Ref legal event code: PK Free format text: BERICHTIGUNG INHABER |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: PD Owner name: LG CHEM, LTD.; KR Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), MERGE; FORMER OWNER NAME: LG LIFE SCIENCES LTD. Effective date: 20170815 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A Owner name: LG CHEM, LTD. Effective date: 20171107 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20171102 AND 20171108 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: PD Owner name: LG CHEM, LTD.; KR Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), FUSIONNER; FORMER OWNER NAME: LG LIFE SCIENCES LTD. Effective date: 20170821 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP Owner name: LG CHEM, LTD., KR Effective date: 20171208 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: PC Ref document number: 473976 Country of ref document: AT Kind code of ref document: T Owner name: LG CHEM, LTD., KR Effective date: 20171207 |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: GB9C Owner name: LG CHEM, LTD., KR Free format text: FORMER OWNER(S): LG LIFE SCIENCES LTD., KR |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13 |
|
REG | Reference to a national code |
Ref country code: SI Ref legal event code: SP73 Owner name: LG CHEM, LTD.; KR Effective date: 20180104 |
|
REG | Reference to a national code |
Ref country code: SK Ref legal event code: PC4A Ref document number: E 8029 Country of ref document: SK Owner name: LG CHEM, LTD., SEOUL, KR Free format text: FORMER OWNER: LG LIFE SCIENCES LTD., SEOUL, KR Effective date: 20190118 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20230221 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: RO Payment date: 20230302 Year of fee payment: 18 Ref country code: LU Payment date: 20230221 Year of fee payment: 18 Ref country code: FR Payment date: 20230221 Year of fee payment: 18 Ref country code: FI Payment date: 20230220 Year of fee payment: 18 Ref country code: DK Payment date: 20230223 Year of fee payment: 18 Ref country code: CZ Payment date: 20230330 Year of fee payment: 18 Ref country code: BG Payment date: 20230222 Year of fee payment: 18 Ref country code: AT Payment date: 20230220 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SK Payment date: 20230307 Year of fee payment: 18 Ref country code: SI Payment date: 20230307 Year of fee payment: 18 Ref country code: SE Payment date: 20230221 Year of fee payment: 18 Ref country code: PT Payment date: 20230224 Year of fee payment: 18 Ref country code: PL Payment date: 20230223 Year of fee payment: 18 Ref country code: IT Payment date: 20230222 Year of fee payment: 18 Ref country code: IS Payment date: 20230221 Year of fee payment: 18 Ref country code: HU Payment date: 20230317 Year of fee payment: 18 Ref country code: GR Payment date: 20230220 Year of fee payment: 18 Ref country code: GB Payment date: 20230220 Year of fee payment: 18 Ref country code: DE Payment date: 20230220 Year of fee payment: 18 Ref country code: BE Payment date: 20230221 Year of fee payment: 18 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230523 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20230426 Year of fee payment: 18 Ref country code: ES Payment date: 20230412 Year of fee payment: 18 Ref country code: CH Payment date: 20230402 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MC Payment date: 20240221 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20240220 Year of fee payment: 19 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240330 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240330 |